


FORM PTO 1390 (REV. 5-93)		US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371		ATTORNEY DOCKET NUMBER 2002_0256A	
		U.S. APPLICATION NO. (if known, see 37 CFR 1.52) NEW <b>10/049822</b>	
International Application No. PCT/JP00/05502	International Filing Date August 17, 2000	Priority Date Claimed August 17, 1999	
Title of Invention A GENETICALLY ENGINEERED cDNA OF RAT bc1-x GENE AND AN IMPROVED PROTEIN			
Applicant(s) For DO/EO/US Shigeo OHTA, Sadamitsu ASOH			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. §371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). <b>ATTACHMENT A</b> 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19. 9. <input checked="" type="checkbox"/> An unexecuted oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). <b>ATTACHMENT B</b> 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). Items 11. to 14. below concern other document(s) or information included: 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <b>ATTACHMENT C</b> 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment. <b>ATTACHMENT D</b> <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment. 14. <input type="checkbox"/> Other items or information:			

THE COMMISSIONER IS AUTHORIZED  
 TO CHARGE ANY DEFICIENCY IN THE  
 FEE FOR THIS PAPER TO DEPOSIT  
 ACCOUNT NO. 23-0975.

U.S. APPLICATION NO. <b>10/049822</b> NEW	INTERNATIONAL APPLICATION NO. PCT/JP00/05502	ATTORNEY'S DOCKET NO. 2002_0256A				
15. [X] The following fees are submitted  <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1040.00 International Search Report has been prepared by the EPO or JPO ..... \$ 890.00 International preliminary examination fee not paid to USPTO but international search paid to USPTO ..... \$ 740.00 International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$ 690.00 International preliminary examination fee paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$ 100.00  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:60%;">CALCULATIONS</th> <th style="width:40%;">PTO USE ONLY</th> </tr> <tr> <td style="height: 100px; vertical-align: bottom;">\$890.00</td> <td></td> </tr> </table>	CALCULATIONS	PTO USE ONLY	\$890.00	
CALCULATIONS	PTO USE ONLY					
\$890.00						
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$				
Claims	Number Filed	Number Extra				
Total Claims	-20 =	X \$18.00				
Independent Claims	- 3 =	X \$84.00				
Multiple dependent claim(s) (if applicable)		+ \$280.00				
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$890.00				
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.		\$				
<b>SUBTOTAL =</b>		\$890.00				
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+				
<b>TOTAL NATIONAL FEE =</b>		\$890.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +		\$				
<b>TOTAL FEES ENCLOSED =</b>		\$890.00				
		Amount to be refunded \$				
		Amount to be charged \$				
a. [X] A check in the amount of \$890.00 to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.						
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b))          must be filed and granted to restore the application to pending status.</b>						
19. CORRESPONDENCE ADDRESS  <div style="text-align: center;">   <b>000513</b>          PATENT TRADEMARK OFFICE       </div>		By: <u>Warren M. Cheek, Jr.</u> Warren M. Cheek, Jr., Registration No. 33,367  WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250  February 19, 2002				



## UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, D.C. 20231  
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/049,822	Shigio Ohta	2002_0256A

000513  
WENDEROTH, LIND & PONACK, L.L.P.  
2033 K STREET N. W.  
SUITE 800  
WASHINGTON, DC 20006-1021

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/JP00/05502

I.A. FILING DATE	PRIORITY DATE
08/17/2000	08/17/1999

CONFIRMATION NO. 6325

371 FORMALITIES LETTER



\*OC00000008194244\*

Date Mailed: 05/30/2002

## NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments

RECEIVED

JUN - 3 2002

WENDEROTH, LIND &amp; PONACK

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).**

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

INDIA L EVANS

Telephone: (703) 305-2936

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO	INTERNATIONAL APPLICATION NO	ATTY DOCKET NO.
10/049,822	PCT/JP00/05502	2002_0256A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Shigeo OHTA et al. : Attn: BOX PCT  
Serial No. NEW : Docket No. 2002\_0256A  
Filed February 19, 2002 :

A GENETICALLY ENGINEERED cDNA OF  
RAT bcl-x GENE AND AN IMPROVED PROTEIN  
[Corresponding to PCT/JP00/05502  
Filed August 17, 2000]

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,  
Washington, DC 20231

Sir:

*Prior to calculating the filing fee,* please amend the above-identified application as follows:

IN THE SPECIFICATION

*Page 1, immediately after the title, please insert:*

This application is a 371 of PCT/JP00/05502 filed August 17, 2000.

*Page 6, lines 17-18, please replace with the following sentence:*

Fig. 21 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein TAT-Bcl-x<sub>L</sub> for 5 days.

*Page 6, lines 20-21, please replace with the following sentence:*

Fig. 22 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein TAT-Bcl-x<sub>L</sub> for 9 days.

ATTACHMENT D

***Page 23, lines 3-5, please replace with the following sentence:***

· Reaction solution (volume 100 µl): 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001% gelatin, 0.2 mM each dATP, dCTP, dTTP, dGTP, AmpliTaqGOLD: 2.5U

***Page 23, line 20 to page 24, line 2, please replace with the following paragraph as follows:***

After the reaction, the PCR solution (75 µl) containing Primer 12 (SEQ ID NO: 17), Primer 10 (final concentration: 1 µM each), and AmpliTaqGOLD (2.5 U) was added, and the PCR was carried out according to the above reaction condition 3. Primer 12 is a sense sequence coding for Met-Gly and the subsequent N-terminal three amino acid residues of TAT-PTD with a cleavage site of the restriction enzyme *Nde* I at the 5'end. The amplified DNA fragment was purified by polyacrylamide gel electrophoresis. After cleavage with *Nde* I, the cleaved end was made blunt with T4DNA polymerase and further subjected to be digested with *Hind* III. The *Escherichia coli* expression vector pROEX1 (Life Technologies) was cleaved with *Nco* I, then made blunt with nuclease S1, followed by digestion with *Hind* III. Two DNAs were ligated each other to yield the recombinant vector pROEX1- *bcl-xY22F/Q26N/R165K* coding for TAT-Bcl-xFNK in which a protein-transduction-domain peptide of TAT protein is fused at the N-terminal.

#### **IN THE CLAIMS**

***Please amend the claims as follows:***

4. (Amended) A recombinant vector carrying the genetically engineered cDNA of claim 1.

***Please add the following new claims:***

9. (New) A recombinant vector carrying the genetically engineered cDNA of claim 2.
10. (New) A recombinant vector carrying the genetically engineered cDNA of claim 3.



[illegible]

The specification has also been amended to correct certain typographical errors. The amendments to page 6 are supported by Example 11 beginning on page 26 of the specification. The amendments to page 23 are to correct obvious errors.

**Favorable action on the merits is solicited.**

Shigeo OHTA et al.

Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
February 19, 2002



DT15 Rec'd PCT/PTO JUN 25 2002

N/A  
#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Confirmation No. 6325  
Shigeo OHTA et al. : Docket No. 2002-0256A  
Serial No. 10/049,822 : Group Art Unit Not Yet Assigned  
Filed April 1, 2002 : Examiner Not Yet Assigned

A GENETICALLY ENGINEERED cDNA OF :  
RAT bc1-x GENE AND AN IMPROVED  
PROTEIN

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents,  
Washington, D.C. 20231

Sir:

Responsive to the Notice dated May 30, 2002, please amend the above-identified  
application as follows:

**In the Specification:**

Page 1, line 1, delete in its entirety.

between lines 3 and 6, insert the following new heading:

Background of the Invention

line 6, replace the heading with the following new heading:

1. Field of the Invention

line 17, replace the heading with the following new heading:

2. Description of the Related Art

Page 3, line 10, replace the heading with the following new heading:

Summary of the Invention

**Page 4, replace the paragraph beginning at line 3 with the following paragraph:**

(6) An improved protein produced from the genetically engineered cDNA of said invention (1), which has at least one amino acid substitution in SEQ ID NO: 2, which the amino acid substitution is selected from the substitutions of residues 22 Tyr with Phe, residues 26 Gln with Asn and residues 165 Arg with Lys.

line 16, replace the heading with the following new heading:

Brief Description of the Drawings

**Page 5, replace the paragraph beginning at line 20 with the following paragraph:**

Fig. 12 shows the results of a test for resistance of the transfected cells to heat treatment.

**replace the paragraph beginning at line 26 with the following paragraph:**

Fig. 14 shows the results of a test for dehydrogenase activity in the transfected cells treated with TN-16 by the WST-1 assay.

**replace the paragraph beginning at line 29 with the following paragraph:**

Fig. 15 shows the results of a test for dehydrogenase activity in the transfected cells treated with staurosporine by the WST-1 assay.

Page 7, line 11, replace the heading with the following new heading:

Description of the Preferred Embodiments

**replace the paragraph beginning at line 13 with the following paragraph:**

The engineered cDNA of the invention as indicated in the above invention (1), is characterized by having at least one substitution selected from the substitutions that change the codon of residues 22 Tyr (tac) to the codons of Phe (ttt/ttc), the codon of residues 26 Gln (cag) to the codons of Asn (aat/aac) and the codon of residues 165 Arg (cgg) to the codons of Lys (aaa/aag), in the coding region of rat *bcl-x* cDNA of SEQ ID NO: 1. In a preferred embodiment, the nucleotide substitutions have occurred in all the above 3 sites in the engineered cDNA of the invention (1). The engineered cDNA which has the nucleotide substitutions at the 3 sites produces the improved protein Bcl-xFNK as shown in the amino acid sequence of SEQ ID NO: 3. In this improved protein Bcl-xFNK, three hydrogen bonds between Tyr<sup>22</sup> and Asp<sup>156</sup>, between Gln<sup>26</sup> and Ser<sup>164</sup> and between Arg<sup>165</sup> and Pro<sup>116</sup>, which are formed in the wild-type rat Bcl-x<sub>L</sub> as shown in the three-dimensional structure of Fig. 1, are disturbed as a result of the amino acid substitutions (Tyr22Phe; Gln26Asn; Arg165Lys) caused by the above-described nucleotide substitutions.

**Page 9, replace the paragraph beginning at line 9 with the following paragraph:**

Among the cells of the invention (5), particularly, the mammalian cells can be also proliferated in a serum-free medium as shown in the data of the Examples below. In general, in order to keep a cultured cell alive for a certain period of time, it is necessary to add a serum (e.g., fetal bovine serum) containing growth factors to the culture medium. Addition of the growth factors can inhibit apoptosis of the cells to prolong the cellular life span. When cellular products such as physiologically active substances or monoclonal antibodies are recovered and purified from the culture medium in which mammalian cells are grown, however, it is desirable that the culture medium contains no impurities such as serum. The reason is that the cost increases and

extra steps are required for purifying the objective substance, and that there is a possibility of the serum containing a risk factor such as a virus. The use of the serum-free and protein-free medium containing no serum, however, practically reduces the degree of cell growth and results in increasing dead cells, when the serum-free and protein-free media have been used. In addition, there is a problem that such increased dead cells might cause contamination of the cellular contents into the culture medium because of an outflow of the cellular contents from the dead cells.

**Page 14, replace the paragraph beginning at line 5 with the following paragraph:**

To construct *bcl-x*Y22F/Q26N, Gln<sup>26</sup> was first substituted with Asn, followed by the amino acid substitution of Tyr<sup>22</sup> with Phe. PCR was carried out using pEF1-BOS*bcl-x* (50 ng) as a template and a pair of the above Primer 1 and Primer 5 (SEQ ID NO:8). Another PCR was carried out using pEF1-BOS*bcl-x* (50 ng) as a template and a pair of the above Primer 4 and Primer 6 (SEQ ID NO:9). The components of the reaction solution (100ml) were the same as above, and the reactions were performed according to the above-described condition 1. Primer 5 is the antisense sequence of *bcl-x*cDNA and contains the nucleotide substitutions to convert the codon of Gln<sup>26</sup> into a codon coding for Asn. Primer 6 is the sense sequence of *bcl-x* cDNA and contains the nucleotide substitutions to convert the codon of Gln<sup>26</sup> into a codon coding for Asn. The nucleotide sequence of 5'-end half of Primer 6 is complementary to that of 5'-end half of Primer 5. Two PCR products amplified by PCR were purified by polyacrylamide gel electrophoresis, and two DNA fragments (6 ng each) were mixed to synthesize the respective complementary strand using AmpliTaqGOLD. The condition for synthesis was the same as the



above reaction condition 2. After the reaction, a PCR reaction solution (75ml) containing Primer 1, Primer 4 (final concentration: 1  $\mu$ M each) and AmpliTaqGOLD (2.5U) were added, and the PCR was carried out according to the above reaction condition 1. The 650-bp PCR product was purified by polyacrylamide gel electrophoresis and then treated with the restriction enzyme *Bam*H I. On the other hand, pEF1-BOS*bcl*-x was treated with *Bam*H I to yield two DNA fragments (5650 bp and 650 bp). The longer DNA fragment (5650 bp) was ligated to the above PCR product in a right orientation to yield the clone pEF1-BOS*bcl*-xQ26N having an amino substitution of Gln26Asn.

**Page 16, replace the paragraph beginning at line 15 with the following paragraph:**

The cells (FDC-P1 or Jurkat) were washed 3 times with an ice-cold K-PBS solution (30.8 mM NaCl, 120.7 mM KCl, 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.46mM KH<sub>2</sub>PO<sub>4</sub>) and suspended in K-PBS containing 5 mM MgCl<sub>2</sub> (Mg-K-PBS) at 10<sup>7</sup> cells/ml. The cell suspension (0.4 ml) was mixed with Mg-K-PBS solution (0.4 ml) in an ice-cold cuvette (Electroporation Cuvettes Plus, 4-mm Gap, BTX, A Division of Genetronics). Then, the linearized pEF1-BOS*bcl*-xY22F/Q26N/R165K (10  $\mu$ g) and the linearized DNA pST-neoB (0.5  $\mu$ g) containing a drug geneticin-resistant gene were added thereto. Change of the volume by addition of the DNA was kept up to 1%. After 10-min incubation on ice, electroporation was carried out to introduce the recombinant vector into cells using the Gene Pulser (250  $\mu$ F and 330V, BioRad). After 10-min incubation on ice, the cells were gently suspended in 39 ml of the fresh culture medium in a 100-mm dish and incubated in a CO<sub>2</sub> incubator. After a lapse of 1 day, the cells were divided and placed in a 96-well plate. Geneticin (GIBCO BRL) was added at 200  $\mu$ g/ml for FDC-P1 cells and

at 1 mg/ml for Jurkat cells to select the geneticin-resistant cells.

**Page 17, replace the paragraph beginning at line 25 with the following paragraph:**

The results are shown in Fig. 2. It was confirmed that the cell transfected with the recombinant vector pEF1-BOS*bcl-xFNK* expresses a protein having the same molecular weight (about 30 kDa) as that expressed in the cells transfected with the clone pEF1-BOS*bcl-x* of the wild-type Bcl-x<sub>L</sub>.

**Page 20, replace the paragraph beginning at line 21 with the following paragraph:**

The results are shown in Figs. 14 and 15. It was confirmed that all independent transfectants expressing the improved Bcl-xFNK exhibited high resistance to treatment with TN-16 and staurosporine, and the dehydrogenase activity was maintained at high level.

**Page 22, replace the paragraph beginning at line 23 with the following paragraph:**

The engineered cDNA coding for Bcl-xFNK prepared in Example 1 was fused to the cDNA coding for the protein transduction domain of TAT protein of HIV virus by 2-step PCR. PCR was carried out using Primer 9 (SEQ ID NO: 14) as the 5'-end primer, Primer 10 (SEQ ID NO: 15) as the 3'-end primer and the recombinant vector pEF1-BOS*bcl-xY22F/Q26N/R165K* having Bcl-xFNK cDNA as a template. Primer 9 is the sense sequence consisting of the 3'-end of TAT-PTD cDNA and the 5'-end (containing the initiation codon) of Bcl-xFNK cDNA. Primer 10 is the antisense sequence consisting of the 3'-end (containing a termination codon) of Bcl-xFNK cDNA and the cleavage site for the restriction enzyme *Hind* III. Details of the PCR reaction are as follows

- Reaction solution (volume 100 µl): 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM

MgCl<sub>2</sub>, 0.001% gelatin, 0.2 mM each dATP, dCTP, dTTP, dGTP, , AmpliTaqGOLD: 2.5U

- Primers: a combination of Primer 9 and Primer 10 (each primer: 1 µM)
- Template DNA: 50 ng
- Reaction condition 3: 94°C/10 min (94°C/30 sec; 49°C/30 sec; 72°C/1 min) ×15

cycles.

**Page 23, replace the paragraph beginning at line 20 with the following paragraph:**

After the reaction, the PCR solution (75 µl) containing Primer 12 (SEQ ID NO: 17), Primer 10 (final concentration: 1 µM each), and AmpliTaqGOLD (2.5 U) was added, and the PCR was carried out according to the above reaction condition 3. Primer 12 is a sense sequence coding for Met-Gly and the subsequent N-terminal three amino acid residues of TAT-PTD with a cleavage site of the restriction enzyme *Nde* I at the 5'-end. The amplified DNA fragment was purified by polyacrylamide gel electrophoresis. After cleavage with *Nde* I, the cleaved end was made blunt with T4DNA polymerase and further subjected to be digested with *Hind* III. The *Escherichia coli* expression vector pROEX1 (Life Technologies) was cleaved with *Nco* I, then made blunt with nuclease S1, followed by digestion with *Hind* III. Two DNAs were ligated to each other to yield the recombinant vector pROEX1- *-bcl-xY22F/Q26N/R165K* coding for TAT-Bcl-xFNK in which a protein-transduction-domain peptide of TAT protein is fused at the N-terminal.

Page 27, line 29 delete the entire heading.

**In the Abstract:**

Page 30, line 1, replace the heading with the following new heading:

**ABSTRACT OF THE DISCLOSURE**

**In the Sequence Listing:**

Please replace the Sequence Listing of record with the attached substitute Sequence Listing.

**In the Claims:**

Above claim 1, insert the following:

What is claimed is:

Please add the following new claims.

13. An isolated polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1, said SEQ ID NO: 1 having at least one nucleotide substitution which changes, in the amino acid sequence encoded by SEQ ID NO: 1, Tyr at amino acid residue 22 to Phe, Gln at amino acid residue 26 to Asn, Arg at amino acid residue 165 to Lys, or a combination thereof.

14. The polynucleotide of claim 13, which is attached at its 5'-end with an oligonucleotide encoding a protein-transduction-domain peptide.

15. The polynucleotide of claim 14, wherein the oligonucleotide encodes the amino acid sequence of SEQ ID NO: 12 or 13.
16. A recombinant vector comprising the polynucleotide of claim 13.
17. A cell into which the recombinant vector of claim 16 was introduced.
18. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 2, said SEQ ID NO: 2 having at least one amino acid substitution selected from the group consisting of substitution of Tyr at amino acid residue 22 to Phe, substitution of Gln at amino acid residue 26 to Asn and substitution of Arg at amino acid residue 165 to Lys.
19. The polypeptide of claim 18, which is attached at the N-terminal with a protein-transduction-domain peptide.
20. The polypeptide of claim 19, wherein the protein-transduction-domain peptide is an oligopeptide comprising the amino acid sequence of SEQ ID NO: 12 or 13.
21. A recombinant vector comprising the polynucleotide of claim 14.
22. A recombinant vector comprising the polynucleotide of claim 15.

23. A cell into which the recombinant vector of claim 21 was introduced.

24. A cell into which the recombinant vector of claim 22 was introduced.

25. The polypeptide of claim 18, wherein said SEQ ID NO: 2 has an amino acid substitution selected from the group consisting of substitution of Tyr at amino acid residue 22 to Phe, substitution of Gln at amino acid residue 26 to Asn, substitution of Arg at amino acid residue 165 to Lys and a combination thereof.

#### **REMARKS**

The foregoing amendments are presented to place the application in better form and in compliance with the sequence rules under 37 CFR 1.821-1.825. In particular, the specification headings have been amended in conformance with U. S. practice, and minor grammatical and spelling errors have been corrected.

Applicants have also submitted a Sequence Listing in both paper and computer readable form as required by 37 C.F.R. 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.

Applicants have also added new claims 13-25 to further protect the present invention. Support for the new claims is readily apparent from the teachings of the specification and the original claims.


Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Shigeo OHTA et al.

By: \_\_\_\_\_

  
Lee Cheng  
Registration No. 40,949  
Attorney for Applicants

LC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
June 25, 2002

DESCRIPTION

**A Genetically Engineered cDNA of Rat *bcl-x* Gene and An Improved Protein**

Background of the Invention

1. Technical Field of the Invention

The present invention relates to a genetically engineered cDNA of rat *bcl-x* gene and an improved protein. More particularly, it relates to a novel cDNA expressing an improved protein of Bcl-x<sub>L</sub> having higher apoptosis-inhibiting activity and cell death-inhibiting activity than the protein Bcl-x<sub>L</sub> expressed by the rat's apoptosis-inhibiting gene *bcl-x*. The invention also relates to materials for utilizing such cDNA in gene engineering, as well as to an improved protein of Bcl-x<sub>L</sub> expressed by the cDNA.

2. Description of the Related Background Art

Apoptosis is one of programmed cell death. Apoptosis is accompanied by poor contact with the surrounding cells, concentration of cytoplasm, condensation of the chromatin and nuclei associated with the endonuclease activity, fragmentation of the nuclei, formation of membrane-bounded apoptotic bodies, and phagocytosis of the apoptotic bodies by the adjacent macrophage or epithelial cells. A phenomenon that the chromosomal DNA is cleaved into DNA fragments of 180 to 200 base length by the endonuclease activity is also observed. Such phenomena have been discussed as the mechanism indicating that the apoptotic bodies are finally phagocytosed by the adjacent cells (for example, Immunology Today 7:115-119, 1986; Science 245:301-305, 1989).

As a gene controlling the apoptosis, for example, the gene *bcl-2* which is



Bcl-x<sub>L</sub> in cells.

Another purpose of the invention is to provide a recombinant vector containing this engineered cDNA and a cell having the recombinant vector.

Still another purpose of the invention is to provide the improved protein expressed from the above-described engineered cDNA.

Summary the  
Disclosure of Invention  
^ ^

In order to solve the above-described problems, the present application provides the following inventions (1) to (8).

(1) A genetically engineered cDNA of the rat *bcl-x* gene, which has at least one substitution selected from the substitutions that change residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys, in the coding region of rat *bcl-x* cDNA of SEQ ID NO: 1.

(2) The genetically engineered cDNA of said invention (1), which is attached at its 5'-end with an oligonucleotide encoding a protein-transduction-domain peptide.

(3) The genetically engineered cDNA of said invention (2), wherein the oligonucleotide encodes the amino acid sequence of SEQ ID NO: 12 or 13.

(4) A recombinant vector carrying the genetically engineered cDNA of any one of said inventions (1) to (3).

(5) A cell into which the recombinant vector of said invention (4) is

introduced.

(6) An improved protein produced from the genetically engineered cDNA of said invention (1), which has at least one amino acid substitution in SEQ ID NO: 2, which the amino acid substitution is selected from the substitutions of residues 22 Tyr with Phe, <sup>residues</sup> ~~residues~~ 26 Gln with Asn and residues 165 Arg with Lys.

(7) The improved protein of said invention (6), which is attached at the N-terminal with a protein-transduction-domain peptide.

(8) The improved protein of said invention (7), wherein the protein-transduction-domain peptide is an oligopeptide having the amino acid sequence of SEQ ID NO: 12 or 13.

#### <sup>the</sup> Brief Description of Drawings

Fig. 1 shows the three-dimensional structure of the wild-type rat Bcl-x<sub>L</sub>.

Fig. 2 shows the results of Western blotting analysis of the expression level of the improved protein Bcl-xLFNK in the transfected cell.

Fig. 3 shows the results of a test for resistance of the transfected cells to apoptosis induced by serum depletion.

Fig. 4 shows the results of a test for resistance of the transfected cells to anti-Fas antibody.

Fig. 5 shows the results of a test for resistance of the transfected cells to staurosporine.

Fig. 6 shows the results of a test for resistance of the transfected cells to TN-16.

Fig. 7 shows the results of a test for resistance of the transfected cells to camptothecin.

Fig. 8 shows the results of a test for resistance of the transfected cells to hydroxyurea.

Fig. 9 shows the results of a test for resistance of the transfected cells to trichostatin A.

Fig. 10 shows the results of a test for resistance of the transfected cells to hydrogen peroxide.

Fig. 11 shows the results of a test for resistance of the transfected cells to paraquat.

Fig. 12 shows the results of a test for resistance of the transfected cells to heat treatment.

Fig. 13 shows the results of a test for dehydrogenase activity in the transfected cells after heat treatment by the WST-1 assay.

Fig. 14 shows the results of a test for dehydrogenase activity in the transfected cells <sup>treated</sup> ~~treated~~ with TN-16 by the WST-1 assay.

Fig. 15 shows the results of a test for dehydrogenase activity in the transfected cells <sup>treated</sup> ~~treated~~ with staurosporine by the WST-1 assay.

administration of dexamethasone.

Fig. 26 is a microscopic photograph showing the liver slice of a mouse to which a solvent (PBS) has been administered systemically, followed by administration of dexamethasone.

Fig. 27 is a microscopic photograph showing the liver slice of a mouse to which a solvent (PBS) only has been administered systemically.

## Description of the Preferred Embodiments

### ~~The Best Mode for Carrying Out the Invention~~

The engineered cDNA of the invention as indicated in the above invention (1), is characterized by having at least one substitution selected from the substitutions that change the codon of residues 22 Tyr (tac) to the codons of Phe (ttt/ttc), the codon of residues 26 Gln (cag) to the codons of Asn (aat/aac) and the codon of residues 165 Arg (cgg) to the codons of Lys (aaa/aag), in the coding region of rat *bcl-x* cDNA of SEQ ID NO: 1. In a preferred embodiment, the nucleotide substitutions have occurred in all the above 3 sites in the engineered cDNA of the invention (1). The engineered cDNA which has the nucleotide substitutions at the 3 sites produces the improved protein Bcl-xFNK as shown in the amino acid sequence of SEQ ID NO: 3. In this improved protein Bcl-xFNK, three hydrogen bonds between Tyr<sup>22</sup> and Asp<sup>156</sup>, between Gln<sup>26</sup> and Ser<sup>164</sup> and between Arg<sup>165</sup> and Pro<sup>116</sup>, which are formed in the wild-type rat Bcl-x<sub>L</sub> as shown in the three-dimensional structure of Fig. 1, are disturbed as a result of the amino acid substitutions (Tyr22Phe; Gln26Asn; Arg165Lys) caused by the above-described nucleotide substitutions.

The engineered cDNA may be prepared by a known method with a mutation kit or a PCR method as mentioned in Examples using the rat *bcl-x* cDNA

invention (4) can be introduced into all of the cells, for example, prokaryotic cells such as *Escherichia coli* or *Bacillus subtilis*; eukaryotic cells such as yeast, insect cells, mammalian cells, or plant cells are included. Introduction of the recombinant vector into cells may be achieved by a known method. For example, when the recombinant vector is introduced into a mammalian cell, electroporation, a calcium phosphate method, a liposome method, a DEAE dextran method, and the like may be employed.

Among the cells of the invention (5), particularly, the mammalian cells can be also proliferated in a serum-free medium as shown in the data of <sup>the</sup> Examples below. In general, in order to keep a cultured cell alive for a certain period of time, it is necessary to add a serum (e.g., fetal bovine serum) containing growth factors to the culture medium. Addition of the growth factors can inhibit apoptosis of the cells to prolong the cellular life span. When cellular products such as physiologically active substances or monoclonal antibodies are recovered and purified from the culture medium in which mammalian cells are grown, however, it is desirous that the culture medium contains no impurities such as serum. The reason is that the cost increases and extra steps are required for purifying the objective substance, and that there is a possibility of the serum containing a risk factor such as <sup>a</sup> virus. The use of the serum-free and protein-free medium containing no serum, however, practically reduces the degree of cell growth and results in increasing dead cells, when the serum-free and protein-free media have been used. In addition, there is a problem that such increased dead cells might cause contamination of the <sup>cellular</sup> ~~cellular~~ contents into the culture medium because of an outflow of the cellular contents from the dead cells.

On the other hand, there is an alternative method for proliferating cells without using any growth factor, wherein the cells are transfected with an proto-oncogene. In this method, however, it has been elucidated that apoptosis is rather promoted by expression of multiple proto-oncogene products.

(having two *Bam*H I sites) was treated with *Bam*H I to yield two DNA fragments (5650 bp and 650 bp). The longer DNA fragment (5650 bp) was ligated to the above PCR product in a right orientation to yield the clone pEF1-BOS*bcl-x*R165K having an amino acid substitution of Arg165Lys.

5 To construct *bcl-x*Y22F/Q26N, Gln<sup>26</sup> was first substituted with Asn, followed by the amino acid substitution of Tyr<sup>22</sup> with Phe. PCR was carried out using pEF1-BOS*bcl-x* (50 ng) as a template and a pair of the above Primer 1 and Primer 5 (SEQ ID NO:8). Another PCR was carried out using pEF1-BOS*bcl-x* (50 ng) as a template and a pair of the above Primer 4 and Primer 6 (SEQ ID NO:9).  
10 The components of the reaction solution (100µl) were the same as above, and the reactions were performed according to the above-described condition 1. Primer 5 is the antisense sequence of *bcl-x*cDNA and contains the nucleotide substitutions to convert the codon of Gln<sup>26</sup> into a codon coding for Asn. Primer 6 is the sense sequence of *bcl-x* cDNA and contains the nucleotide substitutions to convert the  
15 codon of Gln<sup>26</sup> into a codon coding for Asn. The <sup>nucleotide</sup> ~~nucleotide~~ sequence of 5'-end half of Primer 6 is complementary to that of 5'-end half of Primer 5. Two PCR products amplified by PCR were purified by polyacrylamide gel electrophoresis, and two DNA fragments (6 ng each) were mixed to synthesize the respective complementary strand using AmpliTaqGOLD. The condition for synthesis was  
20 the same as the above reaction condition 2. After the reaction, a PCR reaction solution (75µl) containing Primer 1, Primer 4 (final concentration: 1 µM each) and AmpliTaqGOLD (2.5U) were added, and the PCR was carried out according to the above reaction condition 1. The 650-bp PCR product was purified by polyacrylamide gel electrophoresis and then treated with the restriction enzyme  
25 *Bam*H I. On the other hand, pEF1-BOS*bcl-x* was treated with *Bam*H I to yield two DNA fragments (5650 bp and 650 bp). The longer DNA fragment (5650 bp) was ligated to the above PCR product in a right orientation to yield the clone pEF1-BOS*bcl-x*Q26N having an amino substitution of Gln26Asn.

30 Then, two PCR reactions were carried out independently using pEF1-BOS*bcl-x*Q26N as a template. One PCR contained a pair of the above Primer

## Example 2

### Preparation of Transfected Cells

5 A murine premyeloid cell line FDC-P1 were cultured on RPMI1640 medium containing fetal bovine serum (10%) and a cytokine IL-3 (the supernatant of WEHI cell culture broth). A human leukemia cell line Jurkat were cultured on RPMI1640 medium containing fetal bovine serum (10%). The cells were incubated in a CO<sub>2</sub> incubator (5% CO<sub>2</sub>/95% air, 37°C).

10 The recombinant vector pEF1-BOS*bcl-xY22F/Q26N/R165K* prepared in Example 1 was amplified in *Escherichia coli* DH5αMCR (GIBCO BRL) and prepared using the Qiagen Plasmid midi Kit (Qiagen). The recombinant vector was cleaved with *Sca* I (one cleavage site) and the resulting linear DNA was dissolved in 1 mM EDTA solution.

15 The cells (FDC-P1 or Jurkat) were washed 3 times with an ice-cold K-PBS solution (30.8 mM NaCl, 120.7 mM KCl, 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.46mM KH<sub>2</sub>PO<sub>4</sub>) and suspended in K-PBS <sup>containing</sup> 5 mM MgCl<sub>2</sub> (Mg-K-PBS) at 10<sup>7</sup> cells/ml. The cell suspension (0.4 ml) was mixed with Mg-K-PBS solution (0.4 ml) in an ice-cold cuvette (Electroporation Cuvettes Plus, 4-mm Gap, BTX, A Division of  
20 Genetronics). Then, the linearized pEF1-BOS*bcl-xY22F/Q26N/R165K* (10 µg) and the linearized DNA pST-neoB (0.5 µg) containing a drug geneticin-resistant gene were added thereto. Change of the volume by addition of the DNA was kept up to 1%. After 10-min incubation on ice, electroporation was carried out to introduce the recombinant vector into cells using the Gene Pulser (250 µF and  
25 330V, BioRad). After 10-min incubation on ice, the cells were gently suspended in 39 ml of the fresh culture medium in a 100-mm dish and incubated in a CO<sub>2</sub> incubator. After a lapse of 1 day, the cells were divided and placed in a 96-well plate. Geneticin (GIBCO BRL) was added at 200 µg/ml for FDC-P1 cells and at 1 mg/ml for Jurkat cells to select the geneticin-resistant cells.

### Example 3

#### Analysis of expression level of the improved Bcl-xFNK

5 The expression level of the improved protein Bcl-xFNK in the transfected cells prepared in Example 2 was examined by Western blotting. The cells were washed once with PBS (pH 7.4; NaCl 137 mM, Na<sub>2</sub>HPO<sub>4</sub> 8.1 mM, KCl 2.68 mM, KH<sub>2</sub>PO<sub>4</sub> 1.47 mM). After addition of 2% SDS (sodium dodecylsulfate) solution, the cells were disrupted by sonication to solubilize the whole proteins. The  
10 proteins were quantitatively analyzed by the BCA Protein Assay (PIERCE), and 20 µg of protein was fractionated on SDS-polyacrylamide gel electrophoresis (Lemli's system). After the electrophoresis, the protein was blotted on a PVDF membrane (Amersham Pharmacia Biotec). The membrane was immersed in a blocking solution containing fetal bovine serum (10%), and then immersed in a TBS  
15 solution (Tris-HCl pH 7.4 20 mM, NaCl 136 mM, Tween 80 0.2%) containing the murine monoclonal antibody 105-1 (0.5 µg/ml) that reacts with the C-terminal of rat Bcl-x<sub>L</sub>. After incubation at 37°C for 1 hour, the membrane was washed well with TBS, then immersed in a TBS solution containing an HRP (horse radish peroxidase)-binding or AP (alkaline phosphatase)-conjugated secondary antibody,  
20 and incubated at 37°C for 1 hour. The HRP-conjugated secondary antibodies binding to Bcl-x<sub>L</sub> and Bcl-xFNK were visualized on an X-ray film using the RENAISSANCE kit (NEN Life Science Product). The AP-conjugated antibodies binding to Bcl-x<sub>L</sub> and Bcl-xFNK were visualized with the fluoro-image analyzer FLA-2000 (Fuji film) using the ATTOPHOS kit (Boehringer).

25 The results are shown in Fig. 2. It was confirmed that the cell transfected with the recombinant vector pEF1-BOS*bcl-xFNK* expresses a protein having the same molecular weight (about 30 kDa) as that expressed in the cells  
~~transfected~~ <sup>transfected</sup> with the clone pEF1-BOS*bcl-x* of the wild-type Bcl-x<sub>L</sub>.



### Example 5

#### Confirmation of the resistance to the cell death of the FDC-P1*bcl-x*FNK transfectants

For the transfectant FDC-P1*bcl-x*FNK cells prepared in Example 2, the resistance was examined to a variety of apoptosis-inducing stimuli. The results are shown in Figs. 14 to 16. In these figures, the empty marks,  $\diamond$ ,  $\square$ ,  $\triangle$ ,  $\nabla$ , and  $\circ$  represent 5 independent transfectants, FDC-P1*bcl-x*FNK -1, -2, -3, -4, and -5, respectively. The mark  $\bullet$  represents the transfectant FDC-P1*bcl-x* expressing the wild-type Bcl-x<sub>L</sub> at the same expression level. The mark  $\blacksquare$  represents FDC-P1*vec* in which the empty vector plasmid DNA has been introduced.

##### (a) Resistance to TN-16 and staurosporine

The cells were suspended in culture medium at  $2 \times 10^5$  cells/ml, to which TN-16 (50  $\mu$ M) and staurosporine (10 nM) was then added. The dehydrogenase activity of the cells (100  $\mu$ l of the culture broth) was determined daily using the Cell Counting Kit (Dojin Chemical) and WST-1 as a substrate (WST-1 Assay). The enzyme activity was taken as 100% immediately before addition of the agents.

The results are shown in Figs. 14 and 15. It was confirmed that all independent transfectants expressing the improved Bcl-xFNK exhibited high resistance to treatment with TN-16 and staurosporine, and the <sup>dehydrogenase</sup> dehydrogenase activity was maintained at high level.

##### (b) Resistance to apoptosis induced by depletion of the cytokine IL-3

The cells were washed 3 times with PBS and suspended in culture medium containing no IL-3 (but containing serum) at about  $5 \times 10^4$  cells/ml, and the surviving cells were counted by the trypan blue exclusion everyday. The result are shown in Fig. 16, in which the number of the surviving cells immediately after depletion of IL-3 was taken as 100%. In this experiment, the cells other than

### Incubation of the CHO transfectants in serum-free medium

Three transfectants, CHO*bcl-x*, CHO*bcl-xFNK*, and CHO*vec*, prepared in Example 6 were incubated in culture medium DMEM/F-12 containing 10% fetal bovine serum. The cells ( $1 \times 10^3$  cells) were plated in a 100-mm dish containing the medium DMEM/F-12 containing 3% fetal bovine serum. For 5 consecutive days, two thirds of the culture medium was replaced with the DMEM/F-12 containing no fetal bovine serum. The cells were incubated on the medium lacking serum from day 6. The incubation was further continued for another 6 days.

The results are shown in the photograph of Fig. 17. CHO*bcl-xFNK* expressing the improved Bcl-xFNK (Fig. 17C) grew far better than CHO*vec* (Fig. 17B) to which the empty vector was introduced. Additionally, fewer cells were dying or dead and the cells more firmly contacted each other without space in CHO*bcl-xFNK* colonies than those in the colonies of CHO*bcl-x* cells expressing Bcl-xL (Fig. 17A).

From the above results, it was confirmed that the transfected cells of the invention could grow well in a normal state even in a serum-free medium.

### Example 8

#### Construction of a recombinant vector expressing the TAT-Bcl-xFNK protein

The engineered cDNA coding for Bcl-xFNK prepared in Example 1 was fused to the cDNA coding for the protein transduction domain of TAT protein of HIV virus by 2-step PCR. PCR was carried out using Primer 9 (SEQ ID NO: 14) as the 5'-end primer, Primer 10 (SEQ ID NO: 15) as the 3'-end primer and the recombinant vector pEF1-BOS*bcl-xY22F/Q26N/R165K* having Bcl-xFNK cDNA as a template. Primer 9 is the sense sequence consisting of the 3'-end of TAT-PTD cDNA and the 5'-end (containing the initiation codon) of Bcl-xFNK cDNA. Primer 10 is the antisense sequence <sup>consisting</sup> of the 3'-end (containing <sup>a</sup> termination

codon) of Bcl-xFNK cDNA and the cleavage site for the restriction enzyme *Hind* III. Details of the PCR reaction are as follows

Reaction solution (volume 100 ~~μl~~ <sup>μl</sup>): 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001% gelatin, 0.2 mM each dATP, dCTP, dTTP, dGTP, ,

5 AmpliTaqGOLD: 2.5U

Primers: a <sup>combination</sup> ~~combination~~ of Primer 9 and Primer 10 (each primer: 1 μM)

Template DNA: 50 ng

Reaction condition 3: 94°C/10 min (94°C/30 sec; 49°C/30 sec; 72°C/1 min) × 15 cycles.

10 After the reaction, the amplified DNA fragment was purified by polyacrylamide gel electrophoresis. To the above-described PCR reaction solution (25 μl) was added the purified DNA fragment (25 ng) and Primer 11 (SEQ ID NO: 16) to synthesize the complementary strand using AmpliTaqGOLD. Primer 16 is the 5'-end sense sequence coding for the amino acid sequence of TAT-PTD flanked  
15 by Met (initiation codon)-Gly at the 5'-end and Gly- the initiation codon of Bcl-xFNK cDNA at the 3'-end, as shown in SEQ ID NO: 12. The condition for synthesis is as follows.

Reaction condition 4: 94°C/10 min (94°C/30 sec; 53°C to 59°C/30 sec; 72°C/1 min) × 5 cycles

20 After the reaction, the PCR solution (75 ~~μl~~ <sup>μl</sup>) containing Primer 12 (SEQ ID NO: 17), Primer 10 (final concentration: 1 μM each), and AmpliTaqGOLD (2.5 U) was added, and the PCR was carried out according to the above reaction condition 3. Primer 12 is a sense sequence coding for Met-Gly and the subsequent N-terminal three amino acid residues of TAT-PTD with a cleavage site of the  
25 restriction enzyme *Nde* I at the 5'-end. The amplified DNA fragment was purified by polyacrylamide gel electrophoresis. After cleavage with *Nde* I, the cleaved end was made blunt with T4DNA polymerase and further subjected to be digested with *Hind* III. The *Escherichia coli* expression vector pROEX1 (Life Technologies) was cleaved with *Nco* I, then made blunt with nuclease S1, followed by digestion with  
30 *Hind* III. Two DNAs were ligated <sup>to</sup> each other to yield the recombinant vector

pROEX1-*-bcl-xY22F/Q26N/R165K* coding for TAT-Bcl-xFNK in which a protein-transduction-domain peptide of TAT protein is fused at the N-terminal.

### Example 9

#### Preparation of TAT-Bcl-xFNK protein

TAT-Bcl-xFNK protein was expressed in *Escherichia coli* and partially purified as described below. *Escherichia coli* DH5 $\alpha$ MCR carrying pROEX1-*bcl-xY22F/Q26N/R165K* was incubated on 1000 ml of LB liquid medium (5 g yeast extract, 10 g Bactotrypton, and 5 g NaCl) containing ampicillin (50  $\mu$ g/mg) with shaking at 37°C. When the cells reached at the logarithmic growth phase (O.D.600= 0.5), IPTG (isopropyl-1-thio- $\beta$ -galactoside; final concentration 1 mM) was added, and the incubation was continued for 2 hours. TAT-Bcl-xFNK protein was prepared from a soluble fraction and an insoluble fraction (inclusion body) after disrupting the cells. The protein was prepared from the soluble fraction as follows. The harvested cells were washed 3 times with PBS, then suspended in 40 ml of Buffer A (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF), and disrupted by ultrasonication. After centrifugation, TAT-Bcl-xFNK was purified from the supernatant by antibody-affinity chromatography using a column in which was packed a monoclonal antibody 35-32 bound to carriers, said monoclonal antibody being derived from a mouse and recognizing the N-terminal region of rat Bcl-x<sub>L</sub>. TAT-Bcl-xFNK was bound to the antibody, washed, and then eluted with an eluate (50 mM Glycine-HCl pH 2.7, 50 mM NaCl). The eluate was neutralized with 2M Tris-HCl (pH 9.0) and concentrated by Centricon (Amicon). Dialysis against PBS gave TAT-Bcl-xFNK preparation for use in the following experiment. TAT-Bcl-xFNK was prepared from the insoluble fraction (inclusion body) as follows. The harvested cells were washed 3 times with PBS, then suspended in 36 ml of Buffer A (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) containing DTT in place of PMSF,

cell death.

### Example 12

#### 5 Administration of TAT-Bcl-xFNK to mice and confirmation of the inhibition of the death of hepatocytes caused by steroid hormone

Three 8-week old mice (C56BL, 20 g body weight, female) were divided into 3 groups (A, B and C). To the mouse of Group A was intraperitoneally administered PBS solution (0.8 ml) containing 100 µg of TAT-Bcl-xFNK protein (prepared from the soluble fraction). To the mice of Group B and Group C (control) was intraperitoneally administered PBS (0.8 ml) in the same manner. The mice were put back into cages, and after a lapse of 3 hours 0.5 ml of 25% ethanol/PBS solution containing 0.5 mg of a steroid hormone (dexamethasone) was intraperitoneally administered to the mice of Group A and Group B. To the mouse of Group C was intraperitoneally administered 0.5 ml of 25% ethanol/PBS solution. They were put back into cages, and after a lapse of 3 hours killed. Their livers were taken out, and frozen to prepare frozen sections with a cryostat. The sections were stained with hematoxylin-eosin to evaluate the death of hepatocyte. Degeneration of the hepatic tissue and cell death caused by dexamethasone in Group B as shown in Fig. 26 were markedly inhibited by pre-administration of TAT-Bcl-xFNK (Group A; Fig. 25). The degree was shown to be better than that of the control (Group C; Fig. 27).

The above results indicate that the protein TAT-Bcl-xFNK intraperitoneally administered is delivered into the hepatic cells to strongly inhibit cell death caused by dexamethasone.

~~Industrial Applicability~~

## CLAIMS

What is claimed is:

1. A genetically engineered cDNA of the rat *bcl-x* gene, which has at least one substitution selected from the substitutions that change residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys, in the coding region of rat *bcl-x* cDNA of SEQ ID NO: 1.
2. The genetically engineered cDNA of claim 1, which is attached at its 5'-end with an oligonucleotide encoding a protein-transduction-domain peptide.
3. The genetically engineered cDNA of claim 2, wherein the oligonucleotide encodes the amino acid sequence of SEQ ID NO: 12 or 13.
4. A recombinant vector carrying the genetically engineered cDNA of any one of claims 1 to 3.
5. A cell into which the recombinant vector of claim 4 was introduced.
6. An improved protein produced by the genetically engineered cDNA of claim 1, which has at least one amino acid substitution in SEQ ID NO: 2, which amino acid substitution is selected from the substitutions of residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys.
7. The improved protein of claim 6, which is attached at the N-terminal with a protein-transduction-domain peptide.
8. The improved protein of claim 7, wherein the protein-transduction-domain peptide is an oligopeptide having the amino acid sequence of SEQ ID NO: 12 or 13.

3. 6. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.

5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Confirmation No. 6325  
Shigeo OHTA et al. : Docket No. 2002-0256A  
Serial No. 10/049,822 : Group Art Unit Not Yet Assigned  
Filed April 1, 2002 : Examiner Not Yet Assigned

A GENETICALLY ENGINEERED cDNA OF :  
RAT bcl-x GENE AND AN IMPROVED  
PROTEIN

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975

---

**RESPONSE**


Assistant Commissioner for Patents,  
Washington, D.C. 20231

Sir:

Responsive to the Notice dated May 30, 2002, there is submitted herewith, in a separate Preliminary Amendment, a paper copy of a Sequence Listing for the above-identified application which has been prepared in accordance with the sequence rules under 37 CFR 1.821-1.825. The Sequence Listing contains the identical sequences appearing in the original application papers. Thus, no new matter has been added.

There is also submitted herewith a copy of the Sequence Listing in computer readable form as required by 37 CFR 1.821(e). The content of the paper and computer readable copies are the same.

A copy of the Notice is also attached as required.






In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Shigeo OHTA et al.

By: \_\_\_\_\_

  
Lee Cheng  
Registration No. 40,949  
Attorney for Applicants

LC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
June 25, 2002

# SEQUENCE LISTING

<110> OHTA, Shigeo  
ASOH, Sadamitsu

<120> A GENETICALLY ENGINEERED cDNA OF RAT bcl-x GENE AND AN IMPROVED PROTEIN

<130> 2002-0256A/LC/00653

<140> 10/049,822

<141> 2002-04-01

<150> PCT/JP00/05502

<151> 2000-08-17

<150> JP11-230642

<151> 1999-08-17

<160> 17

<170> PatentIn Ver. 2.1

<210> 1

<211> 1742

<212> DNA

<213> Rattus norvegicus

<220>

<221> CDS

<222> (72)..(773)

<300>

<302> An additional form of rat Bcl-x, Bcl-xbeta, generated  
by an unspliced RNA, promotes apoptosis in promyeloid  
cells.

<303> J. Biol. Chem.

<304> 271

<305> 22

<306> 13258-13265

<307> 1996-05-31

<400> 1

```

cacagagcag acccagtgag tgagcaggtg ttttggacaa tggactgggt gagcccatct 60
ctattataaa a atg tct cag agc aac cgg gag ctg gtg gtt gac ttt ctc 110
          Met Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu
            1           5           10
tcc tac aag ctc tcc cag aaa gga tac agc tgg agt cag ttt agc gat 158
Ser Tyr Lys Leu Ser Gln Lys Gly Tyr Ser Trp Ser Gln Phe Ser Asp
      15           20           25
gtc gaa gag aac agg act gaa gcc cca gaa gaa act gaa cca gaa agg 206
Val Glu Glu Asn Arg Thr Glu Ala Pro Glu Glu Thr Glu Pro Glu Arg
      30           35           40           45
gag acc ccc agt gcc atc aat ggc aac cca tcc tgg cac ctg gcg gat 254
Glu Thr Pro Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp
            50           55           60
agc ccc gcg gtg aat gga gcc act ggc cac agc agc agt ttg gat gcg 302
Ser Pro Ala Val Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala

```



Leu Ser Gln Lys Gly Tyr Ser Trp Ser Gln Phe Ser Asp Val Glu Glu  
                   20                  25                  30  
 Asn Arg Thr Glu Ala Pro Glu Glu Thr Glu Pro Glu Arg Glu Thr Pro  
                   35                  40                  45  
 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala  
                   50                  55                  60  
 Val Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala Arg Glu Val  
                   65                  70                  75                  80  
 Ile Pro Met Ala Ala Val Lys Gln Ala Leu Arg Glu Ala Gly Asp Glu  
                   85                  90                  95  
 Phe Glu Leu Arg Tyr Arg Arg Ala Phe Ser Asp Leu Thr Ser Gln Leu  
                   100                  105                  110  
 His Ile Thr Pro Gly Thr Ala Tyr Gln Ser Phe Glu Gln Val Val Asn  
                   115                  120                  125  
 Glu Leu Phe Arg Asp Gly Val Asn Trp Gly Arg Ile Val Ala Phe Phe  
                   130                  135                  140  
 Ser Phe Gly Gly Ala Leu Cys Val Glu Ser Val Asp Lys Glu Met Gln  
                   145                  150                  155                  160  
 Val Leu Val Ser Arg Ile Ala Ser Trp Met Ala Thr Tyr Leu Asn Asp  
                   165                  170                  175  
 His Leu Glu Pro Trp Ile Gln Glu Asn Gly Gly Trp Asp Thr Phe Val  
                   180                  185                  190  
 Asp Leu Tyr Gly Asn Asn Ala Ala Glu Ser Arg Lys Gly Gln Glu  
                   195                  200                  205  
 Arg Phe Asn Arg Trp Phe Leu Thr Gly Met Thr Val Ala Gly Val Val  
                   210                  215                  220  
 Leu Leu Gly Ser Leu Phe Ser Arg Lys  
                   225                  230

<210> 3

<211> 233

<212> PRT

<213> Modified protein

<400> 3

Met Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu Ser Tyr Lys  
                   1                  5                  10                  15  
 Leu Ser Gln Lys Gly Phe Ser Trp Ser Asn Phe Ser Asp Val Glu Glu  
                   20                  25                  30  
 Asn Arg Thr Glu Ala Pro Glu Glu Thr Glu Pro Glu Arg Glu Thr Pro  
                   35                  40                  45  
 Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala  
                   50                  55                  60  
 Val Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala Arg Glu Val  
                   65                  70                  75                  80  
 Ile Pro Met Ala Ala Val Lys Gln Ala Leu Arg Glu Ala Gly Asp Glu  
                   85                  90                  95  
 Phe Glu Leu Arg Tyr Arg Arg Ala Phe Ser Asp Leu Thr Ser Gln Leu  
                   100                  105                  110  
 His Ile Thr Pro Gly Thr Ala Tyr Gln Ser Phe Glu Gln Val Val Asn  
                   115                  120                  125  
 Glu Leu Phe Arg Asp Gly Val Asn Trp Gly Arg Ile Val Ala Phe Phe  
                   130                  135                  140  
 Ser Phe Gly Gly Ala Leu Cys Val Glu Ser Val Asp Lys Glu Met Gln  
                   145                  150                  155                  160  
 Val Leu Val Ser Lys Ile Ala Ser Trp Met Ala Thr Tyr Leu Asn Asp  
                   165                  170                  175

His Leu Glu Pro Trp Ile Gln Glu Asn Gly Gly Trp Asp Thr Phe Val  
                   180                  185                  190  
 Asp Leu Tyr Gly Asn Asn Ala Ala Ala Glu Ser Arg Lys Gly Gln Glu  
                   195                  200                  205  
 Arg Phe Asn Arg Trp Phe Leu Thr Gly Met Thr Val Ala Gly Val Val  
                   210                  215                  220  
 Leu Leu Gly Ser Leu Phe Ser Arg Lys  
 225                  230

<210> 4  
 <211> 26  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<220>  
 <221> base  
 <222> (1)  
 <222> n = a, c, t or g

<220>  
 <221> base  
 <222> (2)  
 <222> n = a, c, t or g

<220>  
 <221> base  
 <222> (3)  
 <222> n = a, c, t or g

<220>  
 <221> base  
 <222> (4)  
 <222> n = a, c, t or g

<220>  
 <221> base  
 <222> (5)  
 <222> n = a, c, t or g

<220>  
 <221> base  
 <222> (6)  
 <222> n = a, c, t or g

<400> 4  
 nnnnnnacta gtggatcctg gaagag

26

<210> 5  
 <211> 28  
 <212> DNA  
 <213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<400> 5  
gcaatcttac tcaccaatac ctgcatct 28

<210> 6  
<211> 27  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<400> 6  
ggtgagtaag attgcaagtt ggatggc 27

<210> 7  
<211> 19  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<400> 7  
tcctggatcc aaggctcta 19

<210> 8  
<211> 28  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<400> 8  
gctaaagtta ctccagctgt atcctttc 28

<210> 9  
<211> 31  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<400> 9  
ctggagtaac tttagcgatg tcgaagagaa c 31

<210> 10  
<211> 26  
<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 10

ccagctgaat cctttctggg agagct 26

<210> 11

<211> 27

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 11

aaaggattca gctggagtaa cttagc 27

<210> 12

<211> 11

<212> PRT

<213> HIV-1

<400> 12

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
1 5 10

<210> 13

<211> 16

<212> PRT

<213> Drosophila

<400> 13

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Phe Lys  
1 5 10 15

<210> 14

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 14

cgtcgtcgtg gtatgtctca gagcaaccgg 30

<210> 15

<211> 34

<212> DNA

<213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<220>  
<221> base  
<222> (1)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (2)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (3)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (4)  
<222> n = a, c, t or g

<400> 15  
nnnnaagctt catcacttcc gactgaagag tgag

34

<210> 16  
<211> 57  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<400> 16  
catatggggtt atggtcgcaa aaaacgccgt cagcgtcgtc gtggtatgtc tcagagc 57

<210> 17  
<211> 26  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Artificial sequence: Synthesized oligonucleotide

<220>  
<221> base  
<222> (1)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (2)  
<222> n = a, c, t or g



<220>  
<221> base  
<222> (3)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (4)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (5)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (6)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (7)  
<222> n = a, c, t or g

<220>  
<221> base  
<222> (8)  
<222> n = a, c, t or g

<400> 17  
nnnnnnnnca tatgggttat ggtcgc

26



DT05 Rec'd PCT/PTO 06 SEP 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 6325**  
Shigeo OHTA et al. : **Docket No. 2002-0256A**  
Serial No. 10/049,822 : **Group Art Unit Not Yet Assigned**  
Filed April 1, 2002 : **Examiner Not Yet Assigned**

A GENETICALLY ENGINEERED cDNA  
OF RAT bc1-x GENE AND AN IMPROVED  
PROTEIN

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE FOR INEFFICIENCY IN THE  
FEES FOR THE LATER TO DEPOSIT  
ACCOUNT NO. 20-0975

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents,  
Washington, D.C. 20231

Sir:

Responsive to the Notice dated August 29, 2002, please amend the above-identified  
application as follows:

**In the Sequence Listing:**

Please replace the Sequence Listing of record with the attached substitute Sequence  
Listing.

REMARKS

The foregoing amendments are presented to place the application in compliance with the sequence rules under 37 CFR 1.821-1.825.


Applicants have submitted a revised Sequence Listing in both paper and computer readable form as required by 37 C.F.R. 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.


Respectfully submitted,

Shigeo OHTA et al.

By: \_\_\_\_\_

  
Lee Cheng  
Registration No. 40,949  
Attorney for Applicants

LC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 6, 2002



|   |   |                                 |
|---|---|---------------------------------|
| In re application of  | : | Confirmation No. 6325           |
| Shigeo OHTA et al.  | : | Docket No. 2002-0256A           |
| Serial No. 10/049,822   | : | Group Art Unit Not Yet Assigned |
| Filed April 1, 2002   | : | Examiner Not Yet Assigned       |
| A GENETICALLY ENGINEERED cDNA<br>OF RAT bcl-x GENE AND AN IMPROVED<br>PROTEIN | : | THE COMMISSIONER IS             |

A copy of the Notice is also attached as required.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the sequence rules under 37 CFR 1.821-1.825. Accordingly, favorable examination on the merits is respectfully requested.

Respectfully submitted,

Shigeo OHTA et al.


By: \_\_\_\_\_

Lee Cheng

Registration No. 40,949

Attorney for Applicants

LC/gtg  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
September 6, 2002



<110> OHTA, Shigeo  
ASOH, Sadamitsu

<130> 2002-0256A/LC/00653

<140> 10/049,822

<141> 2002-04-01

<150> PCT/JP00/05502

<151> 2000-08-17

<150> JP11-230642

<151> 1999-08-17

<160> 17

&lt;170&gt; PatentIn Ver. 2.1

<210> 1

<211> 1742

<212> DNA

<213> Rattus norvegicus

 $\langle 220 \rangle$ 

&lt;221&gt; CDS

<222> (72) .. (773)

 $\langle 300 \rangle$ 

<302> An additional form of rat Bcl-x, Bcl-xbeta, generated by an unspliced RNA, promotes apoptosis in promyeloid cells.

&lt;303&gt; J. Biol. Chem.

<304> 271

<305> 22

<306> 13258-13265

<307> 1996-05-31

 $\langle 400 \rangle$  1

cacagagcag acccagtgag tga gcaggtg ttttggacaa tggactgggtt gagcccatct 60  
ctattataaa a atg tct cag agc aac cgg gag ctg gtg gtt gac ttt etc 110

Met Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu

tcc tac aag ctc tcc cag aaa gga tac agc tgg agt cag ttt agc gat    158  
Ser Tyr Lys Leu Ser Gln Lys Gly Tyr Ser Trp Ser Gln Phe Ser Asp  
            15                20                    25

gtc gaa gag aac agg act gaa gcc cca gaa gaa act gaa cca gaa agg 206  
Val Glu Glu Asn Arg Thr Glu Ala Pro Glu Glu Thr Glu Pro Glu Arg  
30 35 40 45

gag acc ccc agt gcc atc aat ggc aac cca tcc tgg cac ctg gcg gat 254  
Glu Thr Pro Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp  
50 55 60

agc ccc gcg gtg aat gga gcc act ggc cac agc agc agt ttg gat gcg 302  
Ser Pro Ala Val Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala

|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     |     |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|-------------|-------------|------------|-------------|-------------|-------------|-----|-----|-----|-----|-----|-----|-----|------------|-----|-----|------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|-----|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|-----|--|
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 65  |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 70  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75  |  |
| cgg         | gag         | gta        | atc         | ccc         | atg         | gca | gca | gtg | aag | caa | gcg | ctg | aga        | gag | gct | 350  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Arg         | Glu         | Val        | Ile         | Pro         | Met         | Ala | Ala | Val | Lys | Gln | Ala | Leu | Arg        | Glu | Ala |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 80  |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 85  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90  |  |
| ggc         | gat         | gag        | ttt         | gaa         | ctg         | cgg | tac | cgg | aga | gca | ttc | agt | gat        | cta | aca | 398  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Gly         | Asp         | Glu        | Phe         | Glu         | Leu         | Arg | Tyr | Arg | Arg | Ala | Phe | Ser | Asp        | Leu | Thr |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 95  |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 105 |  |
| tcc         | cag         | ctt        | cat         | ata         | acc         | cca | ggg | aca | gca | tat | cag | agc | ttt        | gaa | cag | 446  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Ser         | Gln         | Leu        | His         | Ile         | Thr         | Pro | Gly | Thr | Ala | Tyr | Gln | Ser | Phe        | Glu | Gln |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 110 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 115 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 120 |  |
| gta         | gtg         | aat        | gaa         | ctc         | ttt         | cgg | gat | ggg | gta | aac | tgg | ggg | cgc        | att | gtg | 494  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Val         | Val         | Asn        | Glu         | Leu         | Phe         | Arg | Asp | Gly | Val | Asn | Trp | Gly | Arg        | Ile | Val |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 130 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 135 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 140 |  |
| gcc         | ttc         | ttc        | tcc         | ttt         | ggc         | ggg | gca | ctg | tgc | gtg | gaa | agc | gta        | gac | aag | 542  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Ala         | Phe         | Phe        | Ser         | Phe         | Gly         | Gly | Ala | Leu | Cys | Val | Glu | Ser | Val        | Asp | Lys |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 145 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 155 |  |
| gag         | atg         | cag        | gta         | ttg         | gtg         | agt | cgg | att | gca | agt | tgg | atg | gcc        | acc | tac | 590  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Glu         | Met         | Gln        | Val         | Leu         | Val         | Ser | Arg | Ile | Ala | Ser | Trp | Met | Ala        | Thr | Tyr |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 160 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 165 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 170 |  |
| ctg         | aat         | gac        | cac         | cta         | gag         | cct | tgg | atc | cag | gag | aac | ggc | ggc        | tgg | gac | 638  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Leu         | Asn         | Asp        | His         | Leu         | Glu         | Pro | Trp | Ile | Gln | Glu | Asn | Gly | Gly        | Trp | Asp |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 175 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 180 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 185 |  |
| act         | ttt         | gtg        | gat         | ctc         | tac         | ggg | aac | aat | gca | gca | gcc | gag | agc        | cgg | aaa | 686  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Thr         | Phe         | Val        | Asp         | Leu         | Tyr         | Gly | Asn | Asn | Ala | Ala | Glu | Ser | Arg        | Lys |     |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 190 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 195 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200 |  |
| ggc         | cag         | gag        | cgt         | ttc         | aac         | cgc | tgg | ttc | ctg | acg | ggc | atg | act        | gtg | gct | 734  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Gly         | Gln         | Glu        | Arg         | Phe         | Asn         | Arg | Trp | Phe | Leu | Thr | Gly | Met | Thr        | Val | Ala |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 210 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 215 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 220 |  |
| ggg         | gta         | gtt        | ctg         | ctg         | ggc         | tca | ctc | ttc | agt | cgg | aag | tga | ccagacactg |     |     | 783  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| Gly         | Val         | Val        | Leu         | Leu         | Gly         | Ser | Leu | Phe | Ser | Arg | Lys |     |            |     |     |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
|             |             |            |             |             |             |     |     |     |     |     |     |     |            |     | 225 |      |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 230 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| accgtccact  | cacctctcac  | ctcccacctt | gccccaccca  | caactctctc  | ttcagccacc  |     |     |     |     |     |     |     |            |     |     | 843  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| attgctacca  | ggagaaccac  | tacatgcaac | tcacgcccct  | tccccctatta | taggggttggg |     |     |     |     |     |     |     |            |     |     | 903  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| cctagacgga  | gtccccctgca | gttagctttc | tagaatctac  | cacgcttctg  | tgaaagccac  |     |     |     |     |     |     |     |            |     |     | 963  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| cttcccccca  | catctcagtt  | cccttggcct | caaaactcac  | aagggtttttc | ctcagatcag  |     |     |     |     |     |     |     |            |     |     | 1023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| ctccttggag  | gctggcagga  | gtgggaagg  | gtgtgctaga  | gggagaagag  | cctgccttgt  |     |     |     |     |     |     |     |            |     |     | 1083 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| tgggtgggacc | ctgattaccc  | ctgagcctct | cgggaatgct  | tttctggcag  | ggagctggag  |     |     |     |     |     |     |     |            |     |     | 1143 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| agctctctaa  | acctcttccc  | ccagagacta | gattgccttg  | gttttgatgt  | gtgtggcctc  |     |     |     |     |     |     |     |            |     |     | 1203 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| agaattgatc  | catttcccat  | tctgctgtgt | ccctggggcg  | gctcctcctt  | cccatctcca  |     |     |     |     |     |     |     |            |     |     | 1263 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| cccccccccc  | cccagagcca  | ttgagtggag | tgttttttagc | cctttttgact | aactaaaaat  |     |     |     |     |     |     |     |            |     |     | 1323 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| gcaggctgct  | tgggataacg  | aggcaaggac | ctcctcccca  | cctgtggcct  | ggccaagccc  |     |     |     |     |     |     |     |            |     |     | 1383 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| ccactcctgg  | tctgaatgtt  | ctcctgaggc | ctctggctag  | agtccagccc  | caccagagg   |     |     |     |     |     |     |     |            |     |     | 1443 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| gagggacgga  | gctgcggaaa  | gtccaccctg | cgagagcctg  | agcggctctt  | gcggcttagc  |     |     |     |     |     |     |     |            |     |     | 1503 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| accaccccag  | atccttctcc  | acccctcccc | tggctccatg  | gtgaccatga  | ctgagggacc  |     |     |     |     |     |     |     |            |     |     | 1563 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| aactggggccc | acgctaggtg  | ccccagagct | gttaatgact  | tcagctgcct  | cacttctctgc |     |     |     |     |     |     |     |            |     |     | 1623 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| aagatcagcc  | tgtggcatct  | ttgccttggg | tgtgtggccac | agggtccagg  | gactctggcc  |     |     |     |     |     |     |     |            |     |     | 1683 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |
| ttagcccaga  | agttagagga  | agcttacagc | gcagctatgg  | gagccctggg  | ggcttccct   |     |     |     |     |     |     |     |            |     |     | 1742 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |     |  |

<210> 2  
 <211> 233  
 <212> PRT  
 <213> Rattus norvegicus

<400> 2  
 Met Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu Ser Tyr Lys  
 1 5 10 15

```

Leu Ser Gln Lys Gly Tyr Ser Trp Ser Gln Phe Ser Asp Val Glu Glu
      20      25      30
Asn Arg Thr Glu Ala Pro Glu Glu Thr Glu Pro Glu Arg Glu Thr Pro
      35      40      45
Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala
      50      55      60
Val Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala Arg Glu Val
      65      70      75      80
Ile Pro Met Ala Ala Val Lys Gln Ala Leu Arg Glu Ala Gly Asp Glu
      85      90      95
Phe Glu Leu Arg Tyr Arg Arg Ala Phe Ser Asp Leu Thr Ser Gln Leu
      100      105      110
His Ile Thr Pro Gly Thr Ala Tyr Gln Ser Phe Glu Gln Val Val Asn
      115      120      125
Glu Leu Phe Arg Asp Gly Val Asn Trp Gly Arg Ile Val Ala Phe Phe
      130      135      140
Ser Phe Gly Gly Ala Leu Cys Val Glu Ser Val Asp Lys Glu Met Gln
      145      150      155      160
Val Leu Val Ser Arg Ile Ala Ser Trp Met Ala Thr Tyr Leu Asn Asp
      165      170      175
His Leu Glu Pro Trp Ile Gln Glu Asn Gly Gly Trp Asp Thr Phe Val
      180      185      190
Asp Leu Tyr Gly Asn Asn Ala Ala Glu Ser Arg Lys Gly Gln Glu
      195      200      205
Arg Phe Asn Arg Trp Phe Leu Thr Gly Met Thr Val Ala Gly Val Val
      210      215      220
Leu Leu Gly Ser Leu Phe Ser Arg Lys
      225      230

```

<210> 3

<211> 233

<212> PRT

<213> Artificial Sequence

<220>

<223> Artificial Sequence: Modified Protein of SEQ ID NO: 2

<400> 3

```

Met Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu Ser Tyr Lys
      1      5      10      15
Leu Ser Gln Lys Gly Phe Ser Trp Ser Asn Phe Ser Asp Val Glu Glu
      20      25      30
Asn Arg Thr Glu Ala Pro Glu Glu Thr Glu Pro Glu Arg Glu Thr Pro
      35      40      45
Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala
      50      55      60
Val Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala Arg Glu Val
      65      70      75      80
Ile Pro Met Ala Ala Val Lys Gln Ala Leu Arg Glu Ala Gly Asp Glu
      85      90      95
Phe Glu Leu Arg Tyr Arg Arg Ala Phe Ser Asp Leu Thr Ser Gln Leu
      100      105      110
His Ile Thr Pro Gly Thr Ala Tyr Gln Ser Phe Glu Gln Val Val Asn
      115      120      125
Glu Leu Phe Arg Asp Gly Val Asn Trp Gly Arg Ile Val Ala Phe Phe
      130      135      140
Ser Phe Gly Gly Ala Leu Cys Val Glu Ser Val Asp Lys Glu Met Gln

```



|     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|
| 145 |     | 150 |     | 155 |     | 160 |
| Val | Leu | Val | Ser | Lys | Ile | Ala |
|     |     |     |     | 165 |     |     |
| His | Leu | Glu | Pro | Trp | Ile | Gln |
|     |     |     |     | 170 |     |     |
| Asp | Leu | Tyr | Gly | Asn | Asn | Ala |
|     |     |     |     | 180 |     |     |
| Arg | Phe | Asn | Arg | Trp | Phe | Leu |
|     |     |     |     | 185 |     |     |
| Leu | Leu | Gly | Ser | Leu | Phe | Ser |
|     |     |     |     | 190 |     |     |
|     |     |     |     | 195 |     |     |
|     |     |     |     | 200 |     |     |
|     |     |     |     | 205 |     |     |
|     |     |     |     | 210 |     |     |
|     |     |     |     | 215 |     |     |
|     |     |     |     | 220 |     |     |
|     |     |     |     | 225 |     |     |
|     |     |     |     | 230 |     |     |

<210> 4  
 <211> 26  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<220>  
 <221> base  
 <222> (1)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (2)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (3)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (4)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (5)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (6)  
 <223> n = a, c, t or g

<400> 4  
 nnnnnnacta gtggatcctg gaagag

26

<210> 5  
 <211> 28

...the ... ..

```
<210> 6
<211> 27
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial sequence: Synthesized oligonucleotide

<400> 6
ggtgagtaag attgcaagtt ggatggc
27
```

```
<210> 7
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial sequence: Synthesized oligonucleotide

<400> 7
tcctggatcc aaggctcta
19
```

```
<210> 8
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial sequence: Synthesized oligonucleotide

<400> 8
gctaaagtta ctccagctgt atcctttc
28
```

```
<210> 9
<211> 31
<212> DNA
<213> Artificial sequence

<220>
<223> Artificial sequence: Synthesized oligonucleotide

<400> 9
ctggagtaac tttagcgatg tcgaagagaa c
31
```

<210> 10  
 <211> 26  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<400> 10  
 ccagctgaat cctttctggg agagct 26

<210> 11  
 <211> 27  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<400> 11  
 aaaggattca gctggagtaa ctttagc 27

<210> 12  
 <211> 11  
 <212> PRT  
 <213> HIV-1

<400> 12  
 Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg  
 1 5 10

<210> 13  
 <211> 16  
 <212> PRT  
 <213> Drosophila

<400> 13  
 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Phe Lys  
 1 5 10 15

<210> 14  
 <211> 30  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<400> 14  
 cgtcgtcgtg gtatgtctca gagcaaccgg 30

<210> 15

<211> 34  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<220>  
 <221> base  
 <222> (1)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (2)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (3)  
 <223> n = a, c, t or g

<220>  
 <221> base  
 <222> (4)  
 <223> n = a, c, t or g

<400> 15  
 nnnnaagctt catcacttcc gactgaagag tgag 34

<210> 16  
 <211> 57  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<400> 16  
 catatggggtt atgggtcgcaa aaaacgccgt cagcgtcgtc gtggtatgtc tcagagc 57

<210> 17  
 <211> 26  
 <212> DNA  
 <213> Artificial sequence

<220>  
 <223> Artificial sequence: Synthesized oligonucleotide

<220>  
 <221> base  
 <222> (1)  
 <223> n = a, c, t or g

<220>  
 <221> base

```

<222> (2)
<223> n = a, c, t or g

<220>
<221> base
<222> (3)
<223> n = a, c, t or g

<220>
<221> base
<222> (4)
<223> n = a, c, t or g

<220>
<221> base
<222> (5)
<223> n = a, c, t or g

<220>
<221> base
<222> (6)
<223> n = a, c, t or g

<220>
<221> base
<222> (7)
<223> n = a, c, t or g

<220>
<221> base
<222> (8)
<223> n = a, c, t or g

<400> 17
nnnnnnnnca tatgggttat ggtcgc

```

26

**Version with Markings to**  
**Show Changes Made**

**JC13 Rec'd PCT/PTO 19 FEB 2002**

## **DESCRIPTION**

### **A Genetically Engineered cDNA of Rat *bcl-x* Gene and An Improved Protein**

this application is a 371 of PCT/JP00/05502 filed August 17, 2000.

5

## **Technical Field**

The present invention relates to a genetically engineered cDNA of rat *bcl-x* gene and an improved protein. More particularly, it relates to a novel cDNA  
10 expressing an improved protein of Bcl-x<sub>L</sub> having higher apoptosis-inhibiting activity and cell death-inhibiting activity than the protein Bcl-x<sub>L</sub> expressed by the rat's apoptosis-inhibiting gene *bcl-x*. The invention also relates to materials for utilizing such cDNA in gene engineering, as well as to an improved protein of Bcl-x<sub>L</sub> expressed by the cDNA.

15

## **Background Art**

Apoptosis is one of programmed cell death. Apoptosis is accompanied by  
20 poor contact with the surrounding cells, concentration of cytoplasm, condensation of the chromatin and nuclei associated with the endonuclease activity, fragmentation of the nuclei, formation of membrane-bounded apoptotic bodies, and phagocytosis of the apoptotic bodies by the adjacent macrophage or epithelial cells. A phenomenon that the chromosomal DNA is cleaved into DNA fragments  
25 of 180 to 200 base length by the endonuclease activity is also observed. Such phenomena have been discussed as the mechanism indicating that the apoptotic bodies are finally phagocytosed by the adjacent cells (for example, Immunology Today 7:115-119, 1986; Science 245:301-305, 1989).

30

As a gene controlling the apoptosis, for example, the gene *bcl-2* which is

Version with Markings to  
Show Changes Made

Fig. 16 shows the results of a test for resistance of the transfected cells to apoptosis induced by depletion of the cytokine IL-3.

5            Fig. 17 is a microscopic photograph showing the transfected CHO cells growing in a serum-free medium.

Fig. 18 is a microscopic photograph showing a state of the protein TAT-Bcl-xFNK incorporated in the HeLa cells.

10

Fig. 19 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein TAT-Bcl-xFNK for 5 days.

15            Fig. 20 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein TAT-Bcl-xFNK for 9 days.

✓            Fig. 21 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein <sup>TAT-Bcl-xL</sup>~~Bcl-xFNK~~ for 5 days.

✓            20            Fig. 22 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein <sup>TAT-Bcl-xL</sup>~~Bcl-xFNK~~ for 9 days.

Fig. 23 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing a solvent (PBS) for 5 days.

25

Fig. 24 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing a solvent (PBS) for 9 days.

Fig. 25 is a microscopic photograph showing the liver slice of a mouse to  
30    which the protein TAT-Bcl-xFNK has been administered systemically, followed by

codon) of Bcl-xFNK cDNA and the cleavage site for the restriction enzyme *Hind* III.

Details of the PCR reaction are as follows

- ✓
- Reaction solution (volume <sup>100  $\mu$ l</sup> ~~100 ml~~): 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001% gelatin, 0.2 mM each dATP, dCTP, dTTP, dGTP, ,
  - 5 AmpliTaqGOLD: 2.5U

- Primers: a combination of Primer 9 and Primer 10 (each primer: 1  $\mu$ M)
- Template DNA: 50 ng
- Reaction condition 3: 94°C/10 min (94°C/30 sec; 49°C/30 sec; 72°C/1 min)  $\times$  15 cycles

- 10 After the reaction, the amplified DNA fragment was purified by polyacrylamide gel electrophoresis. To the above-described PCR reaction solution (25  $\mu$ l) was added the purified DNA fragment (25 ng) and Primer 11 (SEQ ID NO: 16) to synthesize the complementary strand using AmpliTaqGOLD. Primer 16 is the 5'-end sense sequence coding for the amino acid sequence of TAT-PTD flanked
- 15 by Met (initiation codon)-Gly at the 5'-end and Gly- the initiation codon of Bcl-xFNK cDNA at the 3'-end, as shown in SEQ ID NO: 12. The condition for synthesis is as follows.

- Reaction condition 4: 94°C/10 min (94°C/30 sec; 53°C to 59°C/30 sec; 72°C/1 min)  $\times$  5 cycles

- ✓
- 20 After the reaction, the PCR solution (<sup>75  $\mu$ l</sup> ~~75 ml~~) containing Primer 12 (SEQ ID NO: 17), Primer 10 (final concentration: 1  $\mu$ M each), and AmpliTaqGOLD (2.5 U) was added, and the PCR was carried out according to the above reaction condition 3. Primer 12 is a sense sequence coding for Met-Gly and the subsequent N-terminal three amino acid residues of TAT-PTD with a cleavage site of the
- 25 restriction enzyme *Nde* I at the 5'-end. The amplified DNA fragment was purified by polyacrylamide gel electrophoresis. After cleavage with *Nde* I, the cleaved end was made blunt with T4DNA polymerase and further subjected to be digested with *Hind* III. The *Escherichia coli* expression vector pROEX1 (Life Technologies) was cleaved with *Nco* I, then made blunt with nuclease S1, followed by digestion with
- 30 *Hind* III. Two DNAs were ligated each other to yield the recombinant vector



Version with Markings to  
Show Changes Made

pROEX1- *-bcl-xY22F/Q26N/R165K* coding for TAT-Bcl-xFNK in which a protein-transduction-domain peptide of TAT protein is fused at the N-terminal.

5

### Example 9

#### Preparation of TAT-Bcl-xFNK protein

TAT-Bcl-xFNK protein was expressed in *Escherichia coli* and partially purified as described below. *Escherichia coli* DH5 $\alpha$ MCR carrying  
10 pROEX1-*bcl-xY22F/Q26N/R165K* was incubated on 1000 ml of LB liquid medium (5 g yeast extract, 10 g Bactotrypton, and 5 g NaCl) containing ampicillin (50  $\mu$ g/mg) with shaking at 37°C. When the cells reached at the logarithmic growth phase (O.D.600= 0.5), IPTG (isopropyl-1-thio- $\beta$ -galactoside; final concentration 1 mM) was added, and the incubation was continued for 2 hours. TAT-Bcl-xFNK  
15 protein was prepared from a soluble fraction and an insoluble fraction (inclusion body) after disrupting the cells. The protein was prepared from the soluble fraction as follows. The harvested cells were washed 3 times with PBS, then suspended in 40 ml of Buffer A (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF), and disrupted by ultrasonication. After centrifugation,  
20 TAT-Bcl-xFNK was purified from the supernatant by antibody-affinity chromatography using a column in which was packed a monoclonal antibody 35-32 bound to carriers, said monoclonal antibody being derived from a mouse and recognizing the N-terminal region of rat Bcl-x<sub>L</sub>. TAT-Bcl-xFNK was bound to the antibody, washed, and then eluted with an eluate (50 mM Glycine-HCl pH 2.7,  
25 50 mM NaCl). The eluate was neutralized with 2M Tris-HCl (pH 9.0) and concentrated by Centricon (Amicon). Dialysis against PBS gave TAT-Bcl-xFNK preparation for use in the following experiment. TAT-Bcl-xFNK was prepared from the insoluble fraction (inclusion body) as follows. The harvested cells were washed 3 times with PBS, then suspended in 36 ml of Buffer A (50 mM Tris-HCl  
30 pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT) containing DTT in place of PMSF,

Version with Markings to  
Show Changes Made

JC13 Rec'd PCT/PTO 19 FEB 2002

### CLAIMS

1. A genetically engineered cDNA of the rat *bcl-x* gene, which has at least one substitution selected from the substitutions that change residues 22 Tyr to Phe,  
5 residues 26 Gln to Asn and residues 165 Arg to Lys, in the coding region of rat *bcl-x* cDNA of SEQ ID NO: 1.
2. The genetically engineered cDNA of claim 1, which is attached at its 5'-end with an oligonucleotide encoding a protein-transduction-domain peptide.
- 10 3. The genetically engineered cDNA of claim 2, wherein the oligonucleotide encodes the amino acid sequence of SEQ ID NO: 12 or 13.
4. <sup>(Amended)</sup> A recombinant vector carrying the genetically engineered cDNA of any one  
15 of claims 1 to 3.
5. A cell into which the recombinant vector of claim 4 was introduced.
6. An improved protein produced by the genetically engineered cDNA of  
20 claim 1, which has at least one amino acid substitution in SEQ ID NO: 2, which amino acid substitution is selected from the substitutions of residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys.
7. The improved protein of claim 6, which is attached at the N-terminal with  
25 a protein-transduction-domain peptide.
8. The improved protein of claim 7, wherein the protein-transduction-domain peptide is an oligopeptide having the amino acid sequence of SEQ ID NO: 12 or 13.

17/pkb

## DESCRIPTION

### A Genetically Engineered cDNA of Rat *bcl-x* Gene and An Improved Protein

5

#### Technical Field

The present invention relates to a genetically engineered cDNA of rat *bcl-x* gene and an improved protein. More particularly, it relates to a novel cDNA  
10 expressing an improved protein of Bcl-x<sub>L</sub> having higher apoptosis-inhibiting activity and cell death-inhibiting activity than the protein Bcl-x<sub>L</sub> expressed by the rat's apoptosis-inhibiting gene *bcl-x*. The invention also relates to materials for utilizing such cDNA in gene engineering, as well as to an improved protein of Bcl-x<sub>L</sub> expressed by the cDNA.

15

#### Background Art

Apoptosis is one of programmed cell death. Apoptosis is accompanied by  
20 poor contact with the surrounding cells, concentration of cytoplasm, condensation of the chromatin and nuclei associated with the endonuclease activity, fragmentation of the nuclei, formation of membrane-bounded apoptotic bodies, and phagocytosis of the apoptotic bodies by the adjacent macrophage or epithelial cells. A phenomenon that the chromosomal DNA is cleaved into DNA fragments  
25 of 180 to 200 base length by the endonuclease activity is also observed. Such phenomena have been discussed as the mechanism indicating that the apoptotic bodies are finally phagocytosed by the adjacent cells (for example, Immunology Today 7:115-119, 1986; Science 245:301-305, 1989).

30

As a gene controlling the apoptosis, for example, the gene *bcl-2* which is

an proto-oncogene found in the human follicular B cell lymphoma is known (Science 226 (4678): 1097-1099, 1984; Pro. Natl. Acad. Sci. USA 81(22): 7166-7170, 1984). Analysis of the gene structure and the transcripts or the cDNA clones have been also reported (Pro. Natl. Acad. Sci. USA 83(14): 5214-5218, 1986; Cell 47(1): 19-28, 1986). This *bcl-2* gene is expressed in immune and nervous systems with high frequency. The gene product is considered to maintain homeostasis of the human immune and nervous systems by inhibiting apoptosis of the cells. Moreover, the *bcl-2* gene is also considered to play an important role in morphogenesis during development since it is widely expressed particularly in the fetus

Thereafter, homologues of the gene *bcl-2* were found in bovine, rat, chicken, etc., and they are collectively called the *bcl-2* family.

The inventors of the present application have cloned rat *bcl-x* gene as a homologue of the human *bcl-x* gene (Cell 74(4): 597-608, 1993) belonging to the *bcl-2* family (J. Biol. Chem. 271(22): 13258-13265, 1996). They have also determined the three-dimensional structure of the Bcl-x<sub>L</sub> protein expressed from the rat *bcl-x* gene by X-ray analysis (J. Biol. Chem. 272(44): 27886-27892, 1997).

The inventors of the present application investigated the substitutions of amino acid residue causing conformational change to enhance the anti-apoptotic activity of rat Bcl-xL. They genetically engineered cDNA of the *bcl-x* gene to replace a specific amino acid residue with other amino acid residue, and finally obtained the engineered cDNA whose product markedly inhibited cell death involving apoptosis.

The invention of the present application was completed based on these new findings by the inventors. The purpose of the invention is to provide the engineered cDNA that allows expression of this novel improved protein of rat

Bcl-x<sub>L</sub> in cells.

Another purpose of the invention is to provide a recombinant vector containing this engineered cDNA and a cell having the recombinant vector.

5

Still another purpose of the invention is to provide the improved protein expressed from the above-described engineered cDNA.

10

### Disclosure of Invention

In order to solve the above-described problems, the present application provides the following inventions (1) to (8).

15 (1) A genetically engineered cDNA of the rat *bcl-x* gene, which has at least one substitution selected from the substitutions that change residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys, in the coding region of rat *bcl-x* cDNA of SEQ ID NO: 1.

20 (2) The genetically engineered cDNA of said invention (1), which is attached at its 5'-end with an oligonucleotide encoding a protein-transduction-domain peptide.

(3) The genetically engineered cDNA of said invention (2), wherein the  
25 oligonucleotide encodes the amino acid sequence of SEQ ID NO: 12 or 13.

(4) A recombinant vector carrying the genetically engineered cDNA of any one of said inventions (1) to (3).

30 (5) A cell into which the recombinant vector of said invention (4) is

introduced.

(6) An improved protein produced from the genetically engineered cDNA of said invention (1), which has at least one amino acid substitution in SEQ ID NO: 2, which the amino acid substitution is selected from the substitutions of residues 22 Tyr with Phe, residues 26 Gln with Asn and residues 165 Arg with Lys.

(7). The improved protein of said invention (6), which is attached at the N-terminal with a protein-transduction-domain peptide.

(8). The improved protein of said invention (7), wherein the protein-transduction-domain peptide is an oligopeptide having the amino acid sequence of SEQ ID NO: 12 or 13.

15

### Brief Description of Drawings

Fig. 1 shows the three-dimensional structure of the wild-type rat Bcl-x<sub>L</sub>.

20

Fig. 2 shows the results of Western blotting analysis of the expression level of the improved protein Bcl-xL<sup>FNK</sup> in the transfected cell.

Fig. 3 shows the results of a test for resistance of the transfected cells to apoptosis induced by serum depletion.

25

Fig. 4 shows the results of a test for resistance of the transfected cells to anti-Fas antibody.

Fig. 5 shows the results of a test for resistance of the transfected cells to staurosporine.

30

Fig. 6 shows the results of a test for resistance of the transfected cells to TN-16.

5 Fig. 7 shows the results of a test for resistance of the transfected cells to camptothecin.

Fig. 8 shows the results of a test for resistance of the transfected cells to hydroxyurea.

10

Fig. 9 shows the results of a test for resistance of the transfected cells to trichostatin A.

Fig. 10 shows the results of a test for resistance of the transfected cells to hydrogen peroxide.

15

Fig. 11 shows the results of a test for resistance of the transfected cells to paraquat.

20 Fig. 12 shows the results of a test for resistance of the transfected cells to heat treatment

Fig. 13 shows the results of a test for dehydrogenase activity in the transfected cells after heat treatment by the WST-1 assay.

25

Fig. 14 shows the results of a test for dehydrogenase activity in the transfected cells treated with TN-16 by the WST-1 assay.

Fig. 15 shows the results of a test for dehydrogenase activity in the transfected cells treated with staurosporine by the WST-1 assay.

30

Fig. 16 shows the results of a test for resistance of the transfected cells to apoptosis induced by depletion of the cytokine IL-3.

5 Fig. 17 is a microscopic photograph showing the transfected CHO cells growing in a serum-free medium.

Fig. 18 is a microscopic photograph showing a state of the protein TAT-Bcl-xFNK incorporated in the HeLa cells.

10

Fig. 19 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein TAT-Bcl-xFNK for 5 days.

Fig. 20 is a microscopic photograph of the chondrocytes in cartilage slice  
15 incubated in a culture medium containing the protein TAT-Bcl-xFNK for 9 days.

Fig. 21 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein Bcl-xFNK for 5 days.

20 Fig. 22 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing the protein Bcl-xFNK for 9 days.

Fig. 23 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing a solvent (PBS) for 5 days.

25

Fig. 24 is a microscopic photograph of the chondrocytes in cartilage slice incubated in a culture medium containing a solvent (PBS) for 9 days.

Fig. 25 is a microscopic photograph showing the liver slice of a mouse to  
30 which the protein TAT-Bcl-xFNK has been administered systemically, followed by





as a template. For the cDNA of rat *bcl-x*, the plasmid pEF1-BOS*bcl-x* (J. Biol. Chem. 271(22): 13258-13265, 1996) can be used. An alternative method may be used, in which an oligonucleotide of any parts of the nucleotide sequence of SEQ ID NO: 1 is synthesized to use as a probe for screening of a rat cDNA library. Or  
 5 an oligonucleotide that hybridizes with both ends of the cDNA fragment to be a subject may be synthesized and used as a primer in an RT-PCR method of preparing the cDNA from the mRNA isolated from rat cells.

The inventions (2) and (3) relates to a DNA fragment (polynucleotide) in  
 10 which an oligonucleotide encoding a protein-transduction-domain peptide is ligated to the 5'-end of the engineered cDNA of the above invention (1). This DNA fragment can be used in preparation of the improved protein of Bcl-x<sub>L</sub> as mentioned below.

15 The recombinant vector in the invention (4) of the present application may be prepared by choosing an appropriate expression vector depending on a type of cell to be introduced (for example, prokaryotic cells such as *Escherichia coli* or *Bacillus subtilis*; eukaryotic cells such as yeast, insect cells, mammalian cells, or plant cells) and integrating therein the engineered cDNA of any one of the  
 20 inventions (1) to (3). For example, when a microorganism such as *Escherichia coli* is employed, any of the engineered cDNAs of the above inventions (1) to (3) is integrated into the DNA cloning site of an expression vector having an replication origin functioning in a microorganism, promoter, ribosome-binding site, terminator, etc. When a eukaryotic cell such as a mammalian cell is employed, a  
 25 recombinant vector of the invention (4) may be prepared using an expression vector for eukaryotic cells having a promoter, splice sites, a poly(A) site, etc.

The cell of the invention (5) is a cell into which the recombinant vector of the invention (4) is introduced and which produces the improved protein of Bcl-x<sub>L</sub>.  
 30 There is no limitation in the type of cell to be used. The recombinant vector of the



The transfected mammalian cells of the invention (5) can be cultivated over a long period of time without accompanying apoptosis even in the absence of any growth factor such as serum since they express the improved protein of Bcl-x<sub>L</sub>.

5 Based on such excellent growth ability, it is possible to establish a cell line.

The improved protein of Bcl-x<sub>L</sub> of the invention (6) is expressed from the engineered cDNA of the invention (1). The protein is characterized by having at least one amino acid substitution in SEQ ID NO: 2, which substitution is selected from the substitutions of Tyr<sup>22</sup> with Phe, Gln<sup>26</sup> with Asn and Arg<sup>165</sup> with Lys. Bcl-xFNK that has the amino acid sequence of SEQ ID NO: 3 containing all of the amino acid substitutions as described above, is the most preferred embodiment..

In producing the improved proteins, the cells of the invention (5) are cultured to yield materials of culture, from which the improved proteins can be isolated and purified by combined known methods for isolation. The known methods for isolation include, for example, treatment with a denaturant or surface activator such as urea, ultra-sonication, digestion with an enzyme, salting-out or precipitation with a solvent, dialysis, centrifugation, ultra-filtration, gel filtration, SDS-PAGE, isoelectric focusing, ion exchange chromatography, hydrophobic chromatography, affinity chromatography, reverse phase chromatography, and the like.

The improved proteins can be used, for example, as active ingredients in apoptosis inhibitors or their leading compounds. Moreover, it is preferable to bind a protein-transduction-domain peptide to the N-terminal of the improved proteins of Bcl-x<sub>L</sub>. The improved protein of Bcl-x<sub>L</sub> having the protein-transduction-domain peptide traverse the cell membrane and enter the cell to exhibit transiently a function of inhibiting apoptosis and cell death. Thus, the improved proteins acquiring such ability to traverse cell membranes can be

utilized, for example in the following uses.

- (a) To maintain cells to be used for implantation in a normal state over a long period of time.
- 5 (b) To maintain organs to be used for transplantation of organs in a normal state over a long period of time.
- (c) To maintain organs subjected to hemostasis in a stable state during a surgical operation
- (d) To use as a therapeutic for cell death caused by cerebral ischemia  
10 accompanying cerebral thrombosis etc.
- (e) To use as a therapeutic for fulminant hepatitis.
- (f) To use as a preventive for cell death caused by excess administration of steroid hormones.
- (g) To use as a therapeutic for diseases accompanied by muscular atrophy  
15 (e.g., muscular dystrophy, myasthenia, myopathy, etc.) caused by death of myocytes.
- (h) To use as a preventive for the death of skin epithelial cells caused by injury or burn.

20 For a protein-transduction-domain peptides, an oligopeptide having the amino acid sequence as shown in SEQ ID NO: 12 or SEQ ID NO: 13 can be used. The oligopeptide of SEQ ID NO: 12 is PTD (protein transduction domain) of HIV-1 TAT. The oligopeptide of SEQ ID NO: 13 is PTD of a homeobox protein, Antennapedia, of *drosophila*.

25 With respect to these protein-transduction-domain peptides, for example, the amino acid sequence and cDNA sequence of HIV-1 TAT are known (Science, 285:1569-1572, 1999; GenBank Accession NO. U39362 M96155). The DNA fragment encoding the region (47th to 57th amino acid sequence of HIV TAT)  
30 corresponding to the PTD is ligated to the engineered cDNA of the invention (1) to



site of the restriction enzyme *Bam*H I. The primer 2 is an antisense sequence of *bcl-x* cDNA, in which the codon of Arg<sup>165</sup> is substituted so as to code for Lys.

For the DNA fragment (B), the primer 3 shown in SEQ ID NO: 6 was used as the 5'-end primer, and the primer 4 shown in SEQ ID NO: 7 as the 3'-end primer. The primer 3 is a sense sequence of *bcl-x* cDNA, in which the codon of Arg<sup>165</sup> is substituted so as to code for Lys, and the nucleotide sequence of 5'-end half is complementary to that of 5'-end half of the primer 2. The primer 4 is an antisense sequence of *bcl-x* cDNA, which corresponds to the amino acid residues 178 to 184 of the coding region. It also contains the cleavage site of the restriction enzyme *Bam*H I. PCR was carried out in the following conditions.

- Reaction solution (volume 100  $\mu$ l): 10mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001% gelatin, 0.2 mM each dATP, dCTP, dTTP, dGTP,
- AmpliTaqGOLD: 2.5U
- A pair of primers: a combination of Primer 1 and Primer 2, and a combination of Primer 3 and Primer 4 (each primer: 1 $\mu$ M)
- Template DNA: 50 ng
- Reaction condition 1: 94°C/10 min; (94°C/30 sec; 53°C/30 sec; 72°C/1 min)x15 cycles

After the reaction, the two amplified DNA fragments (A and B) were purified by polyacrylamide gel electrophoresis. Then, the DNA fragments A and B (6 ng each) were added to the above-described PCR reaction solution (25 $\mu$ l) to synthesize the respective complementary strands using AmpliTaqGOLD. The following reaction condition 2 was employed for the synthesis.

- Reaction condition 2: 94°C/10 min; (94°C/30 sec; 41°C to 47°C/30 sec; 72°C/1 min) x 4 cycles

After the reaction, a PCR reaction solution (75  $\mu$ l) containing Primer 1, Primer 4 (final concentration: 1  $\mu$ M each) and AmpliTaqGOLD (2.5U) were added, and the PCR was carried out according to the above reaction condition 1. The 650-bp PCR product was purified by polyacrylamide gel electrophoresis and then treated with the restriction enzyme *Bam*H I. On the other hand, pEF1-BOS*bcl-x*

(having two *Bam*H I sites) was treated with *Bam*H I to yield two DNA fragments (5650 bp and 650 bp). The longer DNA fragment (5650 bp) was ligated to the above PCR product in a right orientation to yield the clone pEF1-BOS*bcl-xR*165K having an amino acid substitution of Arg165Lys.

5 To construct *bcl-xY22F/Q26N*, Gln<sup>26</sup> was first substituted with Asn, followed by the amino acid substitution of Tyr<sup>22</sup> with Phe. PCR was carried out using pEF1-BOS*bcl-x* (50 ng) as a template and a pair of the above Primer 1 and Primer 5 (SEQ ID NO:8). Another PCR was carried out using pEF1-BOS*bcl-x* (50 ng) as a template and a pair of the above Primer 4 and Primer 6 (SEQ ID NO:9).  
10 The components of the reaction solution (100μl) were the same as above, and the reactions were performed according to the above-described condition 1. Primer 5 is the antisense sequence of *bcl-x*cDNA and contains the nucleotide substitutions to convert the codon of Gln<sup>26</sup> into a codon coding for Asn. Primer 6 is the sense sequence of *bcl-x* cDNA and contains the nucleotide substitutions to convert the  
15 codon of Gln<sup>26</sup> into a codon coding for Asn. The nucleotide sequence of 5'-end half of Primer 6 is complementary to that of 5'-end half of Primer 5. Two PCR products amplified by PCR were purified by polyacrylamide gel electrophoresis, and two DNA fragments (6 ng each) were mixed to synthesize the respective complementary strand using AmpliTaqGOLD. The condition for synthesis was  
20 the same as the above reaction condition 2. After the reaction, a PCR reaction solution (75μl) containing Primer 1, Primer 4 (final concentration: 1 μM each) and AmpliTaqGOLD (2.5U) were added, and the PCR was carried out according to the above reaction condition 1. The 650-bp PCR product was purified by polyacrylamide gel electrophoresis and then treated with the restriction enzyme  
25 *Bam*H I. On the other hand, pEF1-BOS*bcl-x* was treated with *Bam*H I to yield two DNA fragments (5650 bp and 650 bp). The longer DNA fragment (5650 bp) was ligated to the above PCR product in a right orientation to yield the clone pEF1-BOS*bcl-x*Q26N having an amino substitution of Gln26Asn.

Then, two PCR reactions were carried out independently using  
30 pEF1-BOS*bcl-xQ26N* as a template. One PCR contained a pair of the above Primer



1 and Primer 7 (SEQ ID NO: 10) and another PCR contained a pair of the above  
 Primer 4 and Primer 8 (SEQ ID NO: 11). The components of the reaction solution  
 (100  $\mu$ l) were the same as above, and the reactions were performed according to  
 the above-described condition 1. Primer 7 is the antisense sequence of *bcl-x*  
 5 cDNA and contains the nucleotide substitution to convert the codon of Tyr<sup>22</sup> into  
 the codon coding for Phe. Primer 8 is the sense sequence of *bcl-x* cDNA and  
 contains the nucleotide substitution to convert the codon of Tyr<sup>22</sup> into the codon  
 coding for Phe. The nucleotide sequence of 5'-end half of Primer 8 is  
 complementary to that of 5'-end half of Primer 7. Two PCR products amplified by  
 10 PCR were purified by polyacrylamide gel electrophoresis, and two DNA fragments  
 (6 ng each) were mixed to synthesize the respective complementary strand using  
 AmpliTaqGOLD. The condition for synthesis was the same as the above reaction  
 condition 2. After the reaction, a PCR reaction solution (75  $\mu$ l) containing Primer  
 1, Primer 4 (final concentration: 1  $\mu$ M each) and AmpliTaqGOLD (2.5U) were  
 15 subjected to PCR according to the above reaction condition 1. The 650-bp PCR  
 product was purified by polyacrylamide gel electrophoresis and then treated with  
 the restriction enzyme *Bam*H I. On the other hand, pEF1-BOS*bcl-x* was treated  
 with *Bam*H I to yield two DNA fragments (5650 bp and 650 bp). The longer DNA  
 fragment (5650 bp) was ligated to the above PCR product in a right orientation to  
 20 yield the clone pEF1-BOS*bcl-x*Y22F/Q26N having two amino acid substitutions of  
 Tyr22Phe and Gln26Asn.

Finally, pEF1-BOS*bcl-x*R165K and pEF1-BOS*bcl-x*Y22F/Q26N were  
 respectively cleaved with restriction enzymes (*Bgl* II and *Kpn* I). Then, the  
 1000-bp *Bgl* II/*Kpn* I DNA fragment having the amino acid substitutions of  
 25 Tyr22Phe and Gln26Asn, derived from pEF1-BOS*bcl-x*Y22F/Q26N, was ligated to  
 the 5300-bp *Bgl* II/*Kpn* I DNA fragment having the amino acid substitution of  
 Arg165Lys, derived from pEF1-BOS*bcl-x*R165K, to yield the engineered cDNA  
 recombinant vector pEF1-BOS*bcl-x*Y22F/Q26N/R165K coding for the improved  
 protein Bcl-xFNK.

[illegible]

5

10

15

25.

16

### Example 3

#### Analysis of expression level of the improved Bcl-xFNK

5           The expression level of the improved protein Bcl-xFNK in the transfected cells prepared in Example 2 was examined by Western blotting. The cells were washed once with PBS (pH 7.4; NaCl 137 mM, Na<sub>2</sub>HPO<sub>4</sub> 8.1 mM, KCl 2.68 mM, KH<sub>2</sub>PO<sub>4</sub> 1.47 mM). After addition of 2% SDS (sodium dodecylsulfate) solution, the cells were disrupted by sonication to solubilize the whole proteins. The  
10   proteins were quantitatively analyzed by the BCA Protein Assay (PIERCE), and 20 µg of protein was fractionated on SDS-polyacrylamide gel electrophoresis (Lemli's system). After the electrophoresis, the protein was blotted on a PVDF membrane (Amersham Pharmacia Biotec). The membrane was immersed in a blocking solution containing fetal bovine serum (10%), and then immersed in a TBS  
15   solution (Tris-HCl pH 7.4 20 mM, NaCl 136 mM, Tween 80 0.2%) containing the murine monoclonal antibody 105-1 (0.5 µg/ml) that reacts with the C-terminal of rat Bcl-x<sub>L</sub>. After incubation at 37°C for 1 hour, the membrane was washed well with TBS, then immersed in a TBS solution containing an HRP (horse radish peroxidase)-binding or AP (alkaline phosphatase)-conjugated secondary antibody,  
20   and incubated at 37°C for 1 hour. The HRP-conjugated secondary antibodies binding to Bcl-x<sub>L</sub> and Bcl-xFNK were visualized on an X-ray film using the RENAISSANCE kit (NEN Life Science Product). The AP-conjugated antibodies binding to Bcl-x<sub>L</sub> and Bcl-xFNK were visualized with the fluoro-image analyzer FLA-2000 (Fuji film) using the ATTOPHOS kit (Boehringer).

25           The results are shown in Fig. 2. It was confirmed that the cell transfected with the recombinant vector pEF1-BOS*bcl-xFNK* expresses a protein having the same molecular weight (about 30 kDa) as that expressed in the cells transfected with the clone pEF1-BOS*bcl-x* of the wild-type Bcl-x<sub>L</sub>.

#### Example 4

##### Confirmation of resistance to the death of the Jurkat*bcl-x*FNK transfectant

5 For the transfected Jurkat*bcl-x*FNK cells prepared in Example 2, the resistance (non-sensitivity) to a variety of apoptosis-inducing stimuli was examined. The results are shown in Figs. 3 to 13. In these figures, the empty circle (○) represents the transfectant Jurkat*bcl-x*FNK expressing the improved Bcl-xFNK. The filled circle (●) represents the transfectant Jurkat*bcl-x* expressing the wild-type Bcl-xL at the same expression level. The empty square (□) represents Jurkat*vec* cell transfected with the empty vector plasmid DNA. The empty diamond (◇) represents the parent cell Jurkat used in the transfection experiments.

##### (a) Resistance to apoptosis induced by serum withdrawal

15 The cells were washed 3 times with PBS and suspended in RPMI1640 medium containing no serum at  $1 \times 10^5$  cells/ml. The cells were incubated in a CO<sub>2</sub> incubator and the surviving cells were counted by the trypan blue exclusion everyday. The number of the cells was carefully controlled to be less than  $5 \times 10^5$  cells/ml. When the cell number was expected to exceed the limitation, the culture medium was diluted 2 fold. Every 3 days, the half of the serum-free medium was replaced with the fresh medium.

As shown in Fig. 3, the transfected cells expressing the wild-type Bcl-xL was resistant to the serum withdrawal and survived longer than the control parent cells and the vector-transfected cells. The transfected cells expressing the improved Bcl-xFNK survived for a longer period than the wild-type Bcl-xL-expressing cells, from which an excellent apoptosis inhibition effect of Bcl-xFNK was confirmed. Moreover, it was confirmed that the transfected cells could be cultured on serum-free medium.

##### (b) Resistance to anti-Fas antibody

30 The cells were suspended in RPMI1640 medium at  $1 \times 10^5$  cells/ml, to

which anti-Fas antibody (clone CH-11; MBL) was then added at a concentration of 1, 10, 100, or 1000 ng/ml. After incubation for 1 day, the surviving cells were counted by the trypan blue exclusion.

The results are shown in Fig. 4, wherein the number of the cells incubated without the antibody was taken as 100%. As seen clearly from Fig. 4, the transfectant expressing the improved Bcl-xFNK exhibited high resistance to the highly concentrated anti-Fas antibody.

(c) Resistance to a variety of cytotoxic drugs including anti-cancer agents

The cells were suspended in RPMI1640 medium at  $1 \times 10^5$  cells/ml, to which staurosporine (20 nM), TN-16 (10  $\mu$ M), camptothecin (10  $\mu$ M), hydroxyurea (1 mM), trichostatin A (0.25  $\mu$ g/ml), hydrogen peroxide (0.05 mM), or paraquat (1 mM) was then added. And the cells were incubated. The surviving cells were counted by the trypan blue exclusion everyday.

As seen from the results shown in Figs. 5 to 11, the transfectant expressing the improved Bcl-xFNK exhibited high resistance to all of the cytotoxic drugs tested.

(d) Resistance to heat treatment

The cells were suspended in RPMI1640 medium at  $1 \times 10^5$  cells/ml, and incubated at 45°C for 10 minutes. The cells were harvest by centrifugation, then suspended in an equal amount of the fresh culture medium, and incubated at 37°C. The surviving cells were counted by the trypan blue exclusion everyday and shown in Fig. 12. In addition, dehydrogenase activities of the cells (100  $\mu$ l of the culture broth) were determined at 1st day using the Cell Counting Kit (Dojin Chemical) and WST-1 as a substrate (WST-1 Assay). The results are shown in Fig. 13, wherein the enzyme activity of the cells without heat treatment was taken as 100%.

As seen from the above results, it was confirmed that the transfectant expressing the improved Bcl-xFNK exhibited high resistance to heat treatment, and the dehydrogenase activity was maintained at high level even after heat treatment.

## Example 5

### Confirmation of the resistance to the cell death of the FDC-P1*bcl-x*FNK transfectants

For the transfectant FDC-P1*bcl-x*FNK cells prepared in Example 2, the resistance was examined to a variety of apoptosis-inducing stimuli. The results are shown in Figs. 14 to 16. In these figures, the empty marks,  $\diamond$ ,  $\square$ ,  $\triangle$ ,  $\nabla$ , and  $\circ$  represent 5 independent transfectants, FDC-P1*bcl-x*FNK -1, -2, -3, -4, and -5, respectively. The mark  $\bullet$  represents the transfectant FDC-P1*bcl-x* expressing the wild-type Bcl-x<sub>L</sub> at the same expression level. The mark  $\blacksquare$  represents FDC-P1*vec* in which the empty vector plasmid DNA has been introduced.

#### (a) Resistance to TN-16 and staurosporine

The cells were suspended in culture medium at  $2 \times 10^5$  cells/ml, to which TN-16 (50  $\mu$ M) and staurosporine (10 nM) was then added. The dehydrogenase activity of the cells (100  $\mu$ l of the culture broth) was determined daily using the Cell Counting Kit (Dojin Chemical) and WST-1 as a substrate (WST-1 Assay). The enzyme activity was taken as 100% immediately before addition of the agents.

The results are shown in Figs. 14 and 15. It was confirmed that all independent transfectants expressing the improved Bcl-xFNK exhibited high resistance to treatment with TN-16 and staurosporine, and the dehydrogenase activity was maintained at high level.

#### (b) Resistance to apoptosis induced by depletion of the cytokine IL-3

The cells were washed 3 times with PBS and suspended in culture medium containing no IL-3 (but containing serum) at about  $5 \times 10^4$  cells/ml, and the surviving cells were counted by the trypan blue exclusion everyday. The result are shown in Fig. 16, in which the number of the surviving cells immediately after depletion of IL-3 was taken as 100%. In this experiment, the cells other than

FDC-P1<sub>vec</sub> were diluted 5 times with the fresh medium containing no IL-3 every 3rd day.

As seen clearly from Fig. 16, it was confirmed that the transfectants expressing the improved Bcl-xFNK exhibited higher resistance than the transfectant expressing the wild-type Bcl-x<sub>L</sub> to apoptosis induced by depletion of IL-3, and that they could grow even in the absence of IL-3.

### Example 6

#### Preparation of CHO transfectants

Chinese hamster ovary cell CHO were transfected with the recombinant vector pEF1-BOS*bcl-xY22F/Q26N/R165K* prepared in Example 1.

The CHO cells ( $1 \times 10^5$  cells) were suspended in culture medium DMEM/F-12 (GIBCO BRL) containing 10% fetal bovine serum, and incubated in a 60-mm dish overnight. The linearized pEF1-BOS*bcl-xY22F/Q26N/R165K* (10  $\mu$ g) and the linearized pST-neoB (0.5  $\mu$ g) having a drug Geneticin-resistant gene were introduced into the CHO cells using a SuperFect Transfection Reagent kit (Qiagen). As a control, the linearized empty vector pEF1-BOS or the linearized pEF1-BOS*bcl-x* were introduced together with the linearized pST-neoB into the CHO cells. After the transfection treatment, the cells were incubated in culture medium DMEM/F-12 containing 10% fetal bovine serum overnight. Geneticin (700  $\mu$ g/ml) was added, and the incubation was continued to yield the transfected cells. In the same manner as in Example 3, the transfectants expressing the improved protein Bcl-xFNK or the wild-type Bcl-x<sub>L</sub> abundantly and to the same level were selected. Thus, CHO*bcl-x*, CHO*bcl-xFNK*, and CHO<sub>vec</sub> (transfected with the empty vector) were obtained.

### Example 7









and disrupted by ultracentrifugation. Triton X-100 (final concentration 1%) was added, and the mixture was placed on ice for 10 minutes. The inclusion body containing TAT-Bcl-xFNK was precipitated by centrifugation, and washed twice with Buffer A containing Triton X-100. Finally, the inclusion body was solubilized in PBS containing 7M urea and 1 mM DTT. This preparation was confirmed to contain TAT-Bcl-xFNK protein of 70% purity by SDS-polyacrylamide gel electrophoresis and used in the following experiment.

10

### Example 10

#### Incorporation of TAT-Bcl-xFNK protein in cells

TAT-Bcl-xFNK protein (1  $\mu$ M) was added to DMEM/F-12 (Life Technologies) containing 10% FBS (fetal bovine serum), a medium for HeLa cells cultured in a Slide Chamber (Lab-Tek), and the cells were incubated in a CO<sub>2</sub> incubator for 24 hours. The cells were then washed twice with PBS. The cells were fixed with paraformaldehyde (4%) dissolved in PBS at room temperature for 45 min. The cells were washed 3 times with PBS (5 minutes/round), and incubated in PBS containing 10% FBS for 20 min. The cells were washed 3 times with PBS (5 minutes/round), and treated with 1.5% FBS-PBS solution containing an anti-rat Bcl-xL monoclonal antibody 35-32 (murine origin) for 30 min. The cells were washed 3 times with PBS (5 minutes/round), and treated with 1.5% FBS-PBS solution containing an anti-mouse IgG antibody conjugated with FITC, for 30 minutes. The cells were washed 3 times with PBS (5 minutes/round), mounted in PBS, and sealed to observe under a fluorescence microscope.

25

The results are shown in Fig. 18. Spotted fluorescence characteristic to FITC was observed in the cells. This fluorescence signal could not be observed in the cells incubated without TAT-Bcl-xFNK protein. Further, even though the TAT-Bcl-xFNK protein was added, when the cells were not treated with the primary antibody (35-32), no signal was observed. These results indicate that the

30

TAT-Bcl-xFNK protein added to the culture medium has passed through the cellular membrane and has been incorporated in the cells.

5

### Example 11

#### **Introduction of TAT-Bcl-xFNK into the chondrocyte of cartilage slice culture and confirmation of the cell death-inhibiting activity**

10        Cartilage was obtained from the femoral bone head of Osteoarthritis patients undergoing total hip arthroplasty. The cartilage tissue above the subchondral bone (10×10 mm; 1.2 mm in thickness) was aseptically sliced using a single-edged razor. The cartilage slice was placed in a 24-well plate and incubated with an DMEM/Ham F-12 mixed medium (Life Technologies)  
15        containing 20% FBS (fetal bovine serum) at 37°C in a CO<sub>2</sub> incubator. For a comparative experiment, the expression vector of TAT-Bcl-x<sub>L</sub> was constructed in the same manner as TAT-Bcl-xFNK, and TAT-Bcl-x<sub>L</sub> protein was partially purified from *Escherichia coli* (TAT-Bcl-x<sub>L</sub> preparation has the same purity). TAT-Bcl-xFNK (prepared from the inclusion body) or TAT-Bcl-x<sub>L</sub> (prepared from the  
20        inclusion body) were added to the culture medium at a concentration of 0.2 μM. As a control, an equal amount of PBS (a solvent used to solubilize the proteins) containing 7M urea and 1 mM DTT was added. The culture medium containing the protein was changed on day 4 and day 7. After incubation for 4 days and 9 days, the cartilage slice was frozen to prepare frozen sections using a cryostat.  
25        The sections were stained with hematoxylin-eosin to evaluate the death of chondrocyte. As shown in Figs. 19 to 24, the results indicate that TAT-Bcl-xFNK inhibits the death of chondrocyte more strongly than TAT-Bcl-x<sub>L</sub>, and the difference between them is more remarkable on day 9. It was shown that TAT-Bcl-xFNK protein in the culture medium was incorporated into the  
30        chondrocytes buried in the cartilage tissue to exhibit its powerful activity to inhibit



As described above in detail, the invention of the present application provides a engineered cDNA producing an improved protein of rat Bcl-x<sub>L</sub> which exhibits the more enhanced activity to inhibit cell death, a recombinant vector having the engineered cDNA, and cells transfected with the recombinant vectors.

- 5 The transfected cells can be proliferated in a serum-free medium, and are useful for, for example, cell culture systems to efficiently produce useful substances such as physiologically active substances, monoclonal antibodies, and the like. Moreover, the invention of the present application provides an improved protein of rat Bcl-x<sub>L</sub> which exhibits the more enhanced activity to inhibit cell death. The
- 10 improved protein, when it has a protein-transduction-domain peptide, is incorporated into cells and transiently present in the cells to inhibit apoptosis/cell death. The protein is, accordingly, useful as, for example, an ingredient for remedies for various diseases accompanied with cell death or for additives for stably maintaining trans-planted cells or organs.

15

## CLAIMS

1. A genetically engineered cDNA of the rat *bcl-x* gene, which has at least one substitution selected from the substitutions that change residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys, in the coding region of rat *bcl-x* cDNA of SEQ ID NO: 1.
2. The genetically engineered cDNA of claim 1, which is attached at its 5'-end with an oligonucleotide encoding a protein-transduction-domain peptide.
3. The genetically engineered cDNA of claim 2, wherein the oligonucleotide encodes the amino acid sequence of SEQ ID NO: 12 or 13.
4. A recombinant vector carrying the genetically engineered cDNA of any one of claims 1 to 3.
5. A cell into which the recombinant vector of claim 4 was introduced.
6. An improved protein produced by the genetically engineered cDNA of claim 1, which has at least one amino acid substitution in SEQ ID NO: 2, which amino acid substitution is selected from the substitutions of residues 22 Tyr to Phe, residues 26 Gln to Asn and residues 165 Arg to Lys.
7. The improved protein of claim 6, which is attached at the N-terminal with a protein-transduction-domain peptide.
8. The improved protein of claim 7, wherein the protein-transduction-domain peptide is an oligopeptide having the amino acid sequence of SEQ ID NO: 12 or 13.


3000449622 1541240000

10



1/17

Fig. 1



2/17

Fig.2





Fig.3



3/17

Fig.4





Fig.5



4/17

Fig.6





Fig.7



5/17

Fig.8





Fig.9



6/17

Fig. 10





Fig. 11



7/17

Fig.12





Fig.13



8/17

Fig.14






Fig.15





9/17


Fig.16




10/17

Fig.17


A



B




C



11/17

Fig.18



12/17

Fig.19





Fig.20



13/17

Fig.21




Fig.22




14/17

Fig.23




Fig.24




15/17

Fig.25



16/17

Fig.26





17/17

Fig.27



## DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original    () Supplemental    () Substitute    (X) PCT    () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: A GENETICALLY ENGINEERED cDNA OF RAT bc1-x GENE AND AN IMPROVED PROTEIN

of which is described and claimed in:

() the attached specification, or

(X) the specification in application Serial No. \_\_\_\_\_, filed February 19, 2002, and with amendments through \_\_\_\_\_, or

() the specification in International Application No. PCT/JP00/05502, filed August 17, 2000, and as amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

| COUNTRY | APPLICATION NO. | DATE OF FILING  | PRIORITY CLAIMED |
|---------|-----------------|-----------------|------------------|
| Japan   | 1999-230642     | August 17, 1999 | Yes              |
|         |                 |                 |                  |
|         |                 |                 |                  |


I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| APPLICATION SERIAL NO. | U.S. FILING DATE | STATUS: PATENTED, PENDING, ABANDONED |
|------------------------|------------------|--------------------------------------|
|                        |                  |                                      |
|                        |                  |                                      |

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from NISHIZAWA & ASSOCIATES as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

ATTACHMENT B

|   |  |   |  |
|---|--|---|--|
| Direct Correspondence to Customer No:<br><br><div style="text-align: center;"> <br/> <b>000513</b><br/>         PATENT TRADEMARK OFFICE       </div> |  | Direct Telephone Calls to:<br><br>WENDEROTH, LIND & PONACK, L.L.P.<br>2033 "K" Street, N.W., Suite 800<br>Washington, D.C. 20006-1021<br><br>Phone: (202) 721-8200<br>Fax: (202) 721-8250 |  |
|---|--|---|--|

|                                    |   |                                   |   |
|------------------------------------|---|-----------------------------------|---|
| <b>Full Name of First Inventor</b> | FAMILY NAME<br><u>OHTA</u>  | FIRST GIVEN NAME<br><u>Shigeo</u> | SECOND GIVEN NAME                                 |
| <b>Residence &amp; Citizenship</b> | CITY<br><u>Tokyo</u>  | STATE OR COUNTRY<br><u>Japan</u>  | COUNTRY OF CITIZENSHIP<br><u>Japan</u> <u>JPX</u> |
| <b>Post Office Address</b>         | ADDRESS<br><u>1754-35, Hon-machida, Machida-shi, Tokyo, Japan</u> | CITY                              | STATE OR COUNTRY      ZIP CODE                    |

|                                     |  |                                      |   |
|-------------------------------------|--|--------------------------------------|---|
| <b>Full Name of Second Inventor</b> | FAMILY NAME<br><u>ASOH</u>   | FIRST GIVEN NAME<br><u>Sadamitsu</u> | SECOND GIVEN NAME                                 |
| <b>Residence &amp; Citizenship</b>  | CITY<br><u>Kanagawa</u>  | STATE OR COUNTRY<br><u>Japan</u>     | COUNTRY OF CITIZENSHIP<br><u>Japan</u> <u>JPX</u> |
| <b>Post Office Address</b>          | ADDRESS<br><u>224, Kashimada, Saiwai-ku, Kawasaki-shi, Kanagawa, Japan</u> | CITY                                 | STATE OR COUNTRY      ZIP CODE                    |

|                                    |             |                  |                                |
|------------------------------------|-------------|------------------|--------------------------------|
| <b>Full Name of Third Inventor</b> | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME              |
| <b>Residence &amp; Citizenship</b> | CITY        | STATE OR COUNTRY | COUNTRY OF CITIZENSHIP         |
| <b>Post Office Address</b>         | ADDRESS     | CITY             | STATE OR COUNTRY      ZIP CODE |

|                                     |             |                  |                                |
|-------------------------------------|-------------|------------------|--------------------------------|
| <b>Full Name of Fourth Inventor</b> | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME              |
| <b>Residence &amp; Citizenship</b>  | CITY        | STATE OR COUNTRY | COUNTRY OF CITIZENSHIP         |
| <b>Post Office Address</b>          | ADDRESS     | CITY             | STATE OR COUNTRY      ZIP CODE |

|                                    |             |                  |                                |
|------------------------------------|-------------|------------------|--------------------------------|
| <b>Full Name of Fifth Inventor</b> | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME              |
| <b>Residence &amp; Citizenship</b> | CITY        | STATE OR COUNTRY | COUNTRY OF CITIZENSHIP         |
| <b>Post Office Address</b>         | ADDRESS     | CITY             | STATE OR COUNTRY      ZIP CODE |

|                                    |             |                  |                                |
|------------------------------------|-------------|------------------|--------------------------------|
| <b>Full Name of Sixth Inventor</b> | FAMILY NAME | FIRST GIVEN NAME | SECOND GIVEN NAME              |
| <b>Residence &amp; Citizenship</b> | CITY        | STATE OR COUNTRY | COUNTRY OF CITIZENSHIP         |
| <b>Post Office Address</b>         | ADDRESS     | CITY             | STATE OR COUNTRY      ZIP CODE |

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Shigeo Ohta Date March 20, 2002  
Shigeo OHTA  
2nd Inventor Sadamitsu Asoh Date March 20, 2002  
Sadamitsu ASOH  
3rd Inventor \_\_\_\_\_ Date \_\_\_\_\_  
4th Inventor \_\_\_\_\_ Date \_\_\_\_\_  
5th Inventor \_\_\_\_\_ Date \_\_\_\_\_  
6th Inventor \_\_\_\_\_ Date \_\_\_\_\_

The above application may be more particularly identified as follows:

U.S. Application Serial No. \_\_\_\_\_ Filing Date February 19, 2002

Applicant Reference Number 00-F-034US/YS Atty Docket No. 2002 0256A

Title of Invention A GENETICALLY ENGINEERED cDNA OF RAT bc1-x GENE AND AN IMPROVED PROTEIN

SEQUENCE LISTING

<110> Japan Science and Technology Corporation

<120> A mutagenized rat bcl-xL cDNA and a modified protein therefrom

5

<130> NP00291-YS

<140> PCT/JP00/05502

<141> 2000-08-17

10

<150> JP11-230642

<151> 1999-08-17

<160> 17

15

<170> Patent In Ver. 2.1

<210> 1

<211> 1742

20

<212> DNA

<213> Rattus norvegicus

<220>

<221> CDS

<222> (72).. (773)

25

<300>

<302> An additional form of rat Bcl-x, Bcl-xbeta, generated by an unspliced RNA, promotes apoptosis in promyeloid cells.

95                      100                      105

tcc cag ctt cat ata acc cca ggg aca gca tat cag agc ttt gaa cag 446  
 SerG h Leu H is Ile Thr Pro G ly Thr A la Tyr G h Ser Phe G lu G h  
 110 115 120 125  
 gta gtg aat gaa ctc ttt cgg gat ggg gta aac tgg ggt cgc att gtg 494  
 5 ValValAsn G lu Leu Phe Arg Asp G ly ValAsn Trp G ly Arg Ile Val  
 130 135 140  
 gcc ttc ttc tcc ttt ggc ggg gca ctg tgc gtg gaa agc gta gac aag 542  
 A la Phe Phe Ser Phe G ly G ly A la Leu Cys Val G lu Ser Val Asp Lys  
 145 150 155  
 10 gag atg cag gta ttg gtg agt cgg att gca agt tgg atg gcc acc tac 590  
 G luMetG h ValLeu Val Ser Arg Ile A la Ser Trp MetA la Thr Tyr  
 160 165 170  
 ctg aat gac cac cta gag cct tgg atc cag gag aac ggc ggc tgg gac 638  
 Leu Asn Asp H is Leu G lu Pro Trp Ile G h G lu Asn G ly G ly Trp Asp  
 15 175 180 185  
 act ttt gtg gat ctc tac ggg aac aat gca gca gcc gag agc cgg aaa 686  
 Thr Phe Val Asp Leu Tyr G ly Asn Asn A la A la A la G lu Ser Arg Lys  
 190 195 200 205  
 ggc cag gag cgt ttc aac cgc tgg ttc ctg acg ggc atg act gtg gct 734  
 20 G ly G h G lu Arg Phe Asn Arg Trp Phe Leu Thr G lyMetThrValA la  
 210 215 220  
 ggt gta gtt ctg ctg ggc tca ctc ttc agt cgg aag tga ccagacactg 783  
 G lyValValLeu Leu G ly Ser Leu Phe Ser Arg Lys  
 225 230  
 25 accgtccact cacc tcac c tcccacc tt gccccacca caac tc tc tc ttcagccacc 843  
 attgc tacca ggagaaccac taca tgaac tcacgcccc tcccc ta tta taggg ttggg 903  
 cc tagacgga g tcccc tga g ttagc tttc tagaa tc tac cacgc ttc tg tgaagccac 963  
 cttccccca ca tc tcagtt cccttgccct caaaactac aagg tttttc c tcaga tcag 1023

4/11

c tcc ttggag gc tggcagga g tgggaaggg g tg tgc taga gggagaagag cc tgccttg t 1083  
 tgg tgggacc c tga ttaccc c ttagcc tc t cggaag tgc t tttc tggcag ggagc tggag 1143  
 agc tc tc taa acc tc ttccc ccagagac ta ga ttgcttg g ttttga tg t g tg tggcc tc 1203  
 agaa tga tc ca ttcccc t tc tgc tg tg t ccc tggggcg gc tcc tcc tt ccca tc tcca 1263  
 5 ccccccccc cccagagcca ttgag ttagg tgc ttttagc ccttttgact aac taaaaa t 1323  
 gcaggc tgc t tggga taacg aggcaaggac c tcc tcccc cc tg tggcct ggccaagccc 1383  
 ccac tcc tgg tc tga tg tt c tcc ttaggc c tc tggc tag ag tccagccc caccagagag 1443  
 gagggacgga gc tgcgaaa g tccaccc tg cgagagcc tg agcggc tc tt gcggc ttagc 1503  
 accaccccag a tcc ttc tcc acccc tcccc tggc tcca tg g tgacca tga c ttagggacc 1563  
 10 aac tgggccc acgc tagg tg cccagagct g ttaa tgact tcagc tgcct cacttcc tgc 1623  
 aaga tcagcc tg tggca tc t ttgcttggg tgc tggccac aggg tccagg gac tc tggcc 1683  
 ttagccaga ag ttagagga agcttacagc gcagc ta tgg gagccc tggg ggc ttccc t 1742

15 &lt;210&gt; 2

&lt;211&gt; 233

&lt;212&gt; PRT

&lt;213&gt; Rattus norvegicus

&lt;400&gt; 2

20 Met Ser Gln Ser Asn Arg Glu Leu Val Val Asp Phe Leu Ser Tyr Lys

1 5 10 15

Leu Ser Gln Lys Gly Tyr Ser Trp Ser Gln Phe Ser Asp Val Glu Glu

20 25 30

Asn Arg Thr Glu Ala Pro Glu Glu Thr Glu Pro Glu Arg Glu Thr Pro

25 35 40 45

Ser Ala Ile Asn Gly Asn Pro Ser Trp His Leu Ala Asp Ser Pro Ala

50 55 60

Val Asn Gly Ala Thr Gly His Ser Ser Ser Leu Asp Ala Arg Glu Val



5/11

65                      70                      75                      80  
 I l e P r o M e t A l a A l a V a l L y s G h A l a L e u A r g G u A l a G l y A s p G u  
                             85                      90                      95  
 P h e G u L e u A r g T y r A r g A r g A l a P h e S e r A s p L e u T h r S e r G h L e u  
 5                      100                      105                      110  
 H i s I l e T h r P r o G l y T h r A l a T y r G h S e r P h e G u G h V a l V a l A s n  
                             115                      120                      125  
 G u L e u P h e A r g A s p G l y V a l A s n T r p G l y A r g I l e V a l A l a P h e P h e  
                             130                      135                      140  
 10 S e r P h e G l y G l y A l a L e u C y s V a l G u S e r V a l A s p L y s G u M e t G h  
                             145                      150                      155                      160  
 V a l L e u V a l S e r A r g I l e A l a S e r T r p M e t A l a T h r T y r L e u A s n A s p  
                             165                      170                      175  
 H i s L e u G u P r o T r p I l e G h G u A s n G l y G l y T r p A s p T h r P h e V a l  
 15                      180                      185                      190  
 A s p L e u T y r G l y A s n A s n A l a A l a A l a G u S e r A r g L y s G l y G h G u  
                             195                      200                      205  
 A r g P h e A s n A r g T r p P h e L e u T h r G l y M e t T h r V a l A l a G l y V a l V a l  
                             210                      215                      220  
 20 L e u L e u G l y S e r L e u P h e S e r A r g L y s  
                             225                      230

&lt;210&gt; 3

&lt;211&gt; 233

25 &lt;212&gt; PRT

&lt;213&gt; Modified protein

&lt;400&gt; 3

MetSerGhSerAsnArgGuLeuValValAspPheLeuSerTyrLys



225

230

<210> 4

5 <211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

10 <400> 4

nnnnnnacta gtggatcctg gaagag

26

<210> 5

15 <211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

20 <400> 5

gcaatcttac tcaccaatac ctgcatct

28

<210> 6

25 <211> 27

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 6

ggtgagtaag attgcaagtt ggatggc 27

5

<210> 7

<211> 19

<212> DNA

<213> Artificial sequence

10 <220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 7

tcctggatcc aaggctcta 19

15

<210> 8

<211> 28

<212> DNA

<213> Artificial sequence

20 <220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 8

gctaaagtta ctccagctgt atcctttc 28

25

<210> 9

<211> 31

<212> DNA

9/11

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 9

5' ctggagtaac tttagcgatg tcgaagagaa c 31

<210> 10

<211> 26

<212> DNA

10 <213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 10

ccagctgaat cctttctggg agagct 26

15

<210> 11

<211> 27

<212> DNA

20 <213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

<400> 11

aaaggattca gctggagtaa ctttagc 27

25

<210> 12

<211> 11

<212> PRT

&lt;213&gt; HIV-1

<400> 12

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg

5                      1                      5                      10

<210> 13

<211> 16

10 <212> PRT

<213> Drosophila

<400> 13

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Phe Lys

1 5 10 15

<210> 14

30

## <212> DNA

20 <213> Artificial sequence

**<220>**

<223> Artificial sequence: Synthesized oligonucleotide

<400> 14

cgtcgtcgtg gtatgtctca gagcaaccgg 30

25

&lt;210&gt; 15

&lt;211&gt; 34

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

5 <400> 15

nnnnaagctt catcacttcc gactgaagag tgag

34

<210> 16

10 <211> 57

<212> DNA

<213> Artificial sequence

<220>

<223> Artificial sequence: Synthesized oligonucleotide

15 <400> 16

-catatgggtt atggtcgcaa aaaacgccgt cagcgtcgtc gtggtatgtc tcagagc 57

<210> 17

20 <211> 26

<212> DNA

<213> Artificial sequence

<220>


<223> Artificial sequence: Synthesized oligonucleotide

25 <400> 17

nnnnnnnnca tatgggttat ggtcgc

26

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

✓ *Scanned copy is best available. Most of the drawings are dark*